fentanyl has been researched along with Addiction, Opioid in 419 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain." | 9.19 | Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. ( Narayana, A; Passik, SD; Yang, R, 2014) |
| " The reading audience of regional anesthesiologists and acute pain medicine physicians is uniquely positioned to take a lead role in promulgating this care advance amid (i) the unwanted effects of the opioid epidemic and (ii) the uncertain notion of whether routine general anesthesia care (with fentanyl) may indirectly be contributing to the epidemic." | 8.98 | Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care. ( Bahr, MP; Williams, BA, 2018) |
| "Review key aspects of breakthrough pain management with fentanyl buccal tablet, with a focus on minimizing risk to optimize therapeutic outcomes." | 8.86 | Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. ( Fine, PG; Narayana, A; Passik, SD, 2010) |
| "In Fall 2017, we first undertook an assessment of the limits of detection for fentanyl, then tested the three devices' sensitivity and specificity in distinguishing fentanyl in street-acquired drug samples." | 7.96 | An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. ( Clarke, W; Gilbert, M; Green, TC; Lucas, R; McKenzie, M; Park, JN; Sherman, SG; Struth, E, 2020) |
| "This case highlights the importance of acknowledging pregnancy, genetic, or medication-induced changes to fentanyl pharmacokinetics when interpreting urine tests, especially given the potential sequelae of a false-positive urine test result." | 7.96 | Delayed Norfentanyl Clearance During Pregnancy. ( Field, TA; Saia, K; Wanar, A, 2020) |
| "Data from opioid-tolerant patients participating in clinical studies of fentanyl buccal tablet (FBT) for breakthrough pain (up to 18 months of clinical study case-report forms) were retrospectively reviewed and coded for abuse, overdose, and aberrant behavior." | 7.77 | Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. ( Golsorkhi, A; Messina, J; Passik, SD; Xie, F, 2011) |
| "If fentanyl does cause more hyperalgesia compared to other opioids, it does not seem to have a significant impact on opioid consumption after ED discharge." | 5.72 | Association between fentanyl treatment for acute pain in the emergency department and opioid use two weeks after discharge. ( Chauny, JM; Choinière, M; Cournoyer, A; Daoust, R; Emond, M; Gosselin, S; Huard, V; Lang, E; Lavigne, G; Paquet, J; Perry, JJ; Williamson, D; Yan, JW, 2022) |
| "Diffuse alveolar hemorrhage is a rare complication of fentanyl overdose." | 5.43 | Intranasal Fentanyl Intoxication Leading to Diffuse Alveolar Hemorrhage. ( Dunham, M; Ruzycki, S; Sadrzadeh, H; Tremblay, A; Yarema, M, 2016) |
| "Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain." | 5.19 | Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. ( Narayana, A; Passik, SD; Yang, R, 2014) |
| " The reading audience of regional anesthesiologists and acute pain medicine physicians is uniquely positioned to take a lead role in promulgating this care advance amid (i) the unwanted effects of the opioid epidemic and (ii) the uncertain notion of whether routine general anesthesia care (with fentanyl) may indirectly be contributing to the epidemic." | 4.98 | Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care. ( Bahr, MP; Williams, BA, 2018) |
| "Review key aspects of breakthrough pain management with fentanyl buccal tablet, with a focus on minimizing risk to optimize therapeutic outcomes." | 4.86 | Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. ( Fine, PG; Narayana, A; Passik, SD, 2010) |
| "To evaluate the underlying pharmacology, safety, and misuse/abuse of transdermal fentanyl, one of the cornerstone pharmacotherapies for patients with chronic pain." | 4.85 | Transdermal fentanyl: pharmacology and toxicology. ( Nelson, L; Schwaner, R, 2009) |
| " Among those on methadone or buprenorphine (N = 108), multivariable logistic regression models examined the association between socio-demographics, MOUD type; and past-30-day use of heroin/fentanyl; crack; benzodiazepines; and pain medications." | 4.31 | Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs. ( Case, P; Green, TC; Hughto, JMW; Moyo, P; Palacios, WR; Rapisarda, SS; Silcox, J; Stopka, TJ; Tapper, A, 2023) |
| "Positive responses to a fentanyl vaccine were found along with appreciation for the complexity of a vaccine strategy to prevent OD in the setting of pain and uncertain durability." | 4.12 | Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making. ( Blakemore, LM; Cox, R; Dowling, DJ; Kossowsky, J; Levy, O; Levy, S; Needles, EW; Weitzman, ER, 2022) |
| " Cases were categorized based on adherence to a dosing strategy and LDI indication, including OUD and acute pain, non-prescribed fentanyl exposure, and transition from methadone." | 4.12 | Development of an intravenous low-dose buprenorphine initiation protocol. ( Bodnar, AR; Jablonski, LA; Stewart, RW, 2022) |
| "The spread of illegally manufactured opioids, including fentanyl, has brought unprecedented levels of drug overdose deaths in North America." | 4.12 | How much illegally manufactured fentanyl could the U.S. be consuming? ( Caulkins, JP; Kilmer, B; Pardo, B; Reuter, P, 2022) |
| "In this report, we describe 13 cases of drug overdose in Michigan in which valeryl fentanyl was found in postmortem blood." | 4.02 | Thirteen Cases of Valeryl Fentanyl in Michigan: A Call for Expanding Opioid Testing. ( Bush, R; Hunter, B; Jones, P; Markey, M; Moorman, P; Stevens, C; Ton, E, 2021) |
| " Fentanyl, a synthetic opioid, has recently fueled the epidemic, increasing overdose death rates (Centers for Disease Control and Prevention in Drug overdose deaths involving fentanyl, 2011-2016, 2019a, https://www." | 4.02 | Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals. ( Chandra, DK; Copenhaver, MM; Mistler, CB; Shrestha, R; Wickersham, JA, 2021) |
| "In Fall 2017, we first undertook an assessment of the limits of detection for fentanyl, then tested the three devices' sensitivity and specificity in distinguishing fentanyl in street-acquired drug samples." | 3.96 | An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. ( Clarke, W; Gilbert, M; Green, TC; Lucas, R; McKenzie, M; Park, JN; Sherman, SG; Struth, E, 2020) |
| "Immediate-release fentanyl is indicated in the treatment of breakthrough pain in cancer patients who already receive opioids as background chronic analgesia." | 3.96 | [Comparison of hospital consumption of immediate-release fentanyl: use or abuse?] ( Arrieta Loitegui, M; Caro Teller, JM; Ferrari Piquero, JM; Rosas Espinoza, C, 2020) |
| "This case highlights the importance of acknowledging pregnancy, genetic, or medication-induced changes to fentanyl pharmacokinetics when interpreting urine tests, especially given the potential sequelae of a false-positive urine test result." | 3.96 | Delayed Norfentanyl Clearance During Pregnancy. ( Field, TA; Saia, K; Wanar, A, 2020) |
| "Prior studies in heroin use disorder reported low rates (10%) of suicidal intention with non-fatal opioid overdose but did not assess dimensional ratings of suicidal ideation." | 3.91 | Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder. ( Connery, HS; Griffin, M; Kathryn McHugh, R; Kim, J; Rockett, IRH; Taghian, N; Weiss, RD, 2019) |
| " We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl." | 3.91 | Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019) |
| " Recently, drug overdoses caused by fentanyl-laced cocaine specifically are on the rise." | 3.91 | Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced Cocaine Overdose. ( Chen, M; Cheng, J; Feng, Z; Lin, W; Wang, S; Wang, Y; Wu, N; Xie, XQ, 2019) |
| " Committed individuals had significantly higher rates of fentanyl, heroin, and injection drug use, drug overdoses, past incarceration, current criminal justice involvement, and past medication treatment for opioid use (p < ." | 3.88 | Civil commitment experiences among opioid users. ( Anderson, B; Christopher, PP; Stein, MD, 2018) |
| "The study aims to describe recent changes in Kentucky's drug overdose trends related to increased heroin and fentanyl involvement, and to discuss future directions for improved drug overdose surveillance." | 3.85 | Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance. ( Bunn, TL; Costich, JF; Hargrove, SL; Ingram, V; Luu, H; Quesinberry, D; Ralston, W; Singleton, M; Slavova, S; Triplett, JS, 2017) |
| " The buprenorphine transdermal delivery system (BTDS) is indicated for the treatment of moderate to severe chronic pain and provides a continuous dose of 5, 7." | 3.83 | Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. ( Bartelson, BB; Dart, RC; Green, JL; Le Lait, MC; Wiegand, TJ, 2016) |
| "Data from opioid-tolerant patients participating in clinical studies of fentanyl buccal tablet (FBT) for breakthrough pain (up to 18 months of clinical study case-report forms) were retrospectively reviewed and coded for abuse, overdose, and aberrant behavior." | 3.77 | Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. ( Golsorkhi, A; Messina, J; Passik, SD; Xie, F, 2011) |
| " When abused, these sucrose-containing lozenges can cause rampant dental caries." | 3.77 | Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. ( Carunchio, MJ; Mandel, L, 2011) |
| " cloacae bacteremia in a surgical intensive care unit was traced to extrinsic contamination of the parenteral narcotic fentanyl by a health care worker." | 3.71 | Serratia marcescens bacteremia traced to an infused narcotic. ( Arduino, MJ; Bredenberg, HK; Carson, LA; Holt, S; Hutwagner, L; Jarvis, WR; Ostrowsky, BE; Whitener, C, 2002) |
| "To evaluate the proportion of drug abuse related to opioid analgesics and the trends in medical use and abuse of 5 opioid analgesics used to treat severe pain: fentanyl, hydromorphone, meperidine, morphine, and oxycodone." | 3.70 | Trends in medical use and abuse of opioid analgesics. ( Dahl, JL; Gilson, AM; Joranson, DE; Ryan, KM, 2000) |
| "Opioid-induced respiratory depression driven by ligand binding to mu-opioid receptors is a leading cause of opioid-related fatalities." | 3.11 | Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. ( Algera, MH; Dahan, A; Dobbins, R; Gray, F; Groeneveld, GJ; Heath, A; Heuberger, JAAC; Laffont, CM; Moss, LM; Niesters, M; Olofsen, E; Strafford, S; van Velzen, M, 2022) |
| "Flexible take-home dosing buprenorphine/naloxone or supervised methadone models of care for 24 weeks." | 3.11 | Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. ( Bozinoff, N; Bruneau, J; Choi, JC; Hassan, A; Jutras-Aswad, D; Le Foll, B; Lim, R; Mok, WY; Rehm, J; Socias, ME; Wild, TC; Wood, E, 2022) |
| "Fentanyl use was a substantial barrier to XR-NTX initiation for the treatment of OUD in persons with uncontrolled HIV infection." | 3.01 | Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. ( Cook, RR; Fanucchi, L; Foot, C; King, C; Korthuis, PT; Lucas, GM; Lum, PJ; Rodriguez, A; Tookes, H; Torralva, R; Vergara-Rodriguez, P; Waddell, EN, 2021) |
| "Medications for opioid use disorder are effective at reducing risk of fatal overdose but are underutilized, as is the opioid reversal medication naloxone." | 3.01 | Unintentional overdoses: understanding the fentanyl landscape and reducing harm. ( Bell, LA; Hadland, SE, 2023) |
| "Fentanyl has distinct pharmacodynamics and enhanced efficacy relative to other opioids that highlights the need to investigate how females may be uniquely altered by its use." | 3.01 | Focus on fentanyl in females: Sex and gender differences in the physiological and behavioral effects of fentanyl. ( Kosten, TA; Little, KM, 2023) |
| "Although the treatment of opioid use disorder (OUD) is a key element in the response to the opioid overdose epidemic, currently available pharmacotherapies (e." | 2.94 | Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. ( Bach, P; Brar, R; Dong, H; Fairbairn, N; Murphy, SM; Socias, ME; Wood, E, 2020) |
| "The vital signs, withdrawal symptoms and the frequency requirement of fentanyl were recorded during anesthesia, and opioid (pethidine) analgesic was received during the recovery period." | 2.90 | Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia. ( Dehesh, T; Hashemian, M; Jafari, E; Jafari, M; Mahikhan, F; Rahimi, HR, 2019) |
| "Fentanyl is a fully synthetic opioid with analgesic and anesthetic properties." | 2.82 | Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse. ( Cao, L; Han, Y; Lu, L; Shi, J; Yan, W; Yuan, K, 2022) |
| " Specifically, in patients with chronic fentanyl or other drug exposures, some clinicians are using alternative buprenorphine induction strategies, such as quickly maximizing buprenorphine agonist effects (eg, macrodosing) or, conversely, giving smaller initial doses and slowing the rate of buprenorphine dosing to avoid antagonist/withdrawal effects (eg, microdosing)." | 2.82 | A Neuropharmacological Model to Explain Buprenorphine Induction Challenges. ( Azar, P; Greenwald, MK; Herring, AA; Nelson, LS; Perrone, J, 2022) |
| "The incidence of opioid use disorder (OUD) and overdose deaths is rising yearly within the United States." | 2.82 | Pharmacotherapy of Opioid Use Disorder-Update and Current Challenges. ( Buresh, M; Fingerhood, M; Racha, S, 2022) |
| " This study examined the duration of action of BUP at microORs and correlations with pharmacokinetic and pharmacodynamic outcomes in 10 heroin-dependent volunteers." | 2.73 | Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ( Bueller, J; Chang, Y; Greenwald, M; Johanson, CE; Kilbourn, M; Koeppe, R; Moody, DE; Zubieta, JK, 2007) |
| "The widespread misuse of opioids and opioid use disorder (OUD) together constitute a major public health crisis in the United States." | 2.72 | A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y ( Ben Nathan, J; Doyle, RP; Hayes, MR; Herman, R; Merkel, R; Milliken, BT; Moreno, A; Rahematpura, S; Schmidt, HD; Stecyk, K; Zeb, S; Zhang, Y, 2021) |
| "Fentanyl has been FDA approval as an analgesic since 1968 and multiple different fentanyl preparations have been developed over the years." | 2.66 | Reasons to avoid fentanyl. ( Behm, B; Davis, MP, 2020) |
| "Fentanyl was shown to be the most prescribed strong opioid in outpatient settings in Germany, despite not being the first-line choice for chronic pain conditions." | 2.61 | Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence. ( Neicun, J; Roman-Urrestarazu, A; Rosner, B; Yang, JC, 2019) |
| "Fentanyl is a powerful opioid anesthetic and analgesic, the use of which has caused an increasing public health threat in the United States and elsewhere." | 2.61 | The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. ( Han, Y; Khan, MZ; Lu, L; Yan, W; Yuan, K; Zheng, Y, 2019) |
| "Carfentanil is a synthetic fentanyl analogue approved for veterinary use." | 2.61 | Carfentanil: a narrative review of its pharmacology and public health concerns. ( Juurlink, DN; Leen, JLS, 2019) |
| "Within five years of initial prescription opioid misuse, 3." | 2.58 | Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts. ( Rose, ME, 2018) |
| "While prescription opioid abuse is part of the opioid problem, it is by no means the entirety of it." | 2.58 | Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. ( LeQuang, JA; Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain." | 2.58 | Abuse of fentanyl: An emerging problem to face. ( Grzonkowski, P; Kacprzak, Ł; Kuczyńska, K; Zawilska, JB, 2018) |
| " On the basis of current guidelines, as well as in terms of the lack of data regarding long-term use of opioids and their effectiveness beyond a period of 3 months, this development must be viewed critically." | 2.49 | [Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency]. ( Gossrau, G; Heineck, R; Kaiser, U; Sabatowski, R; Scharnagel, R; Schütze, A, 2013) |
| " Specifically, a technique based on pharmacokinetic modeling is described that predicts safe and therapeutic opioid dosing in these patients." | 2.43 | Postoperative care of the chronic opioid-consuming patient. ( Davis, JJ; Johnson, KB; Swenson, JD, 2005) |
| " Though the use of opioid analgesics for the treatment of acute pain appears to be generally benign, long-term administration of opioids has been associated with clinically meaningful rates of abuse or addiction." | 2.43 | Major increases in opioid analgesic abuse in the United States: concerns and strategies. ( Compton, WM; Volkow, ND, 2006) |
| "Societal fears of opioid addiction and lack of advocacy are also causal factors in the under-treatment of pediatric pain." | 2.41 | Pain management in the critically ill child. ( Nichols, DG; Yaster, M, 2001) |
| "Fentanyl is a highly lipophilic mu opioid receptor agonist, increasingly found in heroin and other drug supplies, that is contributing to marked increases in opioid-related overdose and may be complicating treatment of opioid use disorder (OUD)." | 1.91 | Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance. ( Choi, CJ; Comer, S; Jones, J; Luba, R, 2023) |
| "Funding communities to address substance use disorders and related problems of concern, rather than targeting funding toward a specific type of drug, may result in better health outcomes throughout the entire community." | 1.91 | Rural communities face more than an opioid crisis: Reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity. ( Baker, R; Bresani, E; Byrne, F; Carpenedo Mun, C; Meyers, K; Schuler, H, 2023) |
| "Buprenorphine alone was present in 32 deaths, of which 20 were considered the direct cause of death (0." | 1.91 | Characterization of Unintentional Deaths Among Buprenorphine Users. ( Abate, MA; Dai, Z; Kraner, JC; Limen, GN; Mock, AR; Smith, GS, 2023) |
| " During the dose-response test, females given limited access to fentanyl demonstrated increased motivation to acquire fentanyl compared to males." | 1.91 | Chronic inflammatory pain promotes place preference for fentanyl in male rats but does not change fentanyl self-administration in male and female rats. ( Barattini, AE; Edwards, KN; Edwards, S; Gilpin, NW; Montanari, C; Pahng, AR, 2023) |
| "One of the biggest challenges to treat OUD is the relapse to drug seeking after prolonged abstinence." | 1.91 | IGF-1 Microinjection in the Prefrontal Cortex Attenuates Fentanyl-Seeking Behavior in Mice. ( Li, G; Singh, A; Wang, Y; Wang, ZJ; Yue, S, 2023) |
| "Methadone medication treatment for opioid use disorder appears to remain an effective intervention for reducing illicit opioid use." | 1.91 | Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. ( Dawson, E; Gordon, AJ; Passik, S; Saloner, B; Stein, BD; Whitley, P, 2023) |
| " Both exposures were also associated with a reduced probability and reduced total dosage of opioid administration in the PACU." | 1.91 | Association of Intraoperative Opioid Administration With Postoperative Pain and Opioid Use. ( Balanza, G; Bharadwaj, KM; Bittner, EA; Das, P; Deng, H; Gutierrez, R; Horgan, C; Houle, TT; Johnson, JJ; Liu, R; Macdonald, T; Pandit, A; Purdon, PL; Santa Cruz Mercado, LA; Stone, TAD; Tou, SLJ, 2023) |
| "Buprenorphine treatment for opioid use disorder (OUD) has more than doubled since 2009." | 1.91 | Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. ( Beaudoin, FL; Berk, J; Chambers, LC; Gaither, R; Hallowell, BD; Hampson, AJ; Paiva, TJ; Wightman, RS; Zullo, AR, 2023) |
| "Number of opioid overdose deaths, people incarcerated, and associated costs over 5 years." | 1.91 | Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. ( Barocas, JA; Gonsalves, G; Jurecka, C; Savinkina, A, 2023) |
| "Naloxone was prescribed in 16." | 1.91 | Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department. ( Ali, SA; Bedder, M; Harris, R; Shell, J, 2023) |
| " The overall morphine milligram equivalents (MME) per 24 hours of this dosage form available in the hospital were reduced from 56,073." | 1.72 | Optimization of the medication-use process for fentanyl patches at a small community hospital. ( Glowczewski, J; Roberts, P; Wise, C, 2022) |
| "Hospitalizations among patients with opioid use disorder (OUD) are also rising; and, hospitalized patients are at increased risk of overdose and death following hospital discharge." | 1.72 | Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality. ( Cook, R; Englander, H; Goff, A; King, CA; Korthuis, PT; Leahy, JM; Morris, CD; Wheelock, H, 2022) |
| "If fentanyl does cause more hyperalgesia compared to other opioids, it does not seem to have a significant impact on opioid consumption after ED discharge." | 1.72 | Association between fentanyl treatment for acute pain in the emergency department and opioid use two weeks after discharge. ( Chauny, JM; Choinière, M; Cournoyer, A; Daoust, R; Emond, M; Gosselin, S; Huard, V; Lang, E; Lavigne, G; Paquet, J; Perry, JJ; Williamson, D; Yan, JW, 2022) |
| "In response to rising rates of opioid dependence and fatal poisonings, measures were instituted to decrease the prescription, diversion, and nonmedical use of POs including prescription drug monitoring programs (PDMPs), pain clinic laws, prescription duration limits, disciplining doctors who prescribed an excessive number of POs, and the advent of abuse deterrent formulations of POs." | 1.72 | The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis. ( Dickson-Gomez, J; Green Montaque, HD; Krechel, S; Li, J; Ohlrich, J; Spector, A; Weeks, M, 2022) |
| " A need exists to adapt methadone dosing from opioid treatment programs (OTPs) in this era." | 1.72 | Adapting methadone inductions to the fentanyl era. ( Buresh, M; Nahvi, S; Steiger, S; Weinstein, ZM, 2022) |
| "Naloxone was included to determine the feasibility of combining naloxone with buprenorphine in the formulation as an abuse deterrent." | 1.72 | A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys. ( Comer, SD; Foltin, RW; Nagaraj, N; Scranton, RE; Sykes, KA; Zale, S, 2022) |
| "Fentanyl has come to dominate the U." | 1.72 | Characteristics and correlates of fentanyl preferences among people with opioid use disorder. ( Dusek, K; Gryczynski, J; Hochstatter, KR; Mitchell, SG; Schwartz, RP; Terplan, M; Wireman, K, 2022) |
| "A retrospective cohort of cancer patients who died between 2011 and 2014 and were exposed as outpatient to a strong opioid analgesic in the last year of life was identified in the Echantillon Généraliste de Bénéficiaires (a 1/97th random sample of the French general population)." | 1.72 | Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. ( Chu, TH; Lapeyre-Mestre, M; Palmaro, A; Rueter, M, 2022) |
| " Oxycodone is the most widely abused opioid analgesic and it appears to predispose to chronic use with high likability by users." | 1.62 | Relative addictive potential of opioid analgesic agents. ( Connors, NJ; Kim, HK; Mazer-Amirshahi, M; Motov, S, 2021) |
| "2016 fentanyl decedents were more likely to have naloxone administered upon overdose, and the majority still had a positive prescription history for a controlled substance." | 1.62 | The fentanyl phase of the opioid epidemic in Cuyahoga County, Ohio, United States. ( Deo, VS; Gilson, TP; Kaspar, C; Singer, ME, 2021) |
| "Buprenorphine was effective in both sexes and eliminated sex and estrous phase differences in drug-seeking." | 1.62 | A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse. ( Bakhti-Suroosh, A; Lynch, WJ; Towers, EB, 2021) |
| "Carfentanil for example has an estimated potency 10,000 times greater than morphine and thus is highly dangerous for human use." | 1.62 | A Highly Efficacious Carfentanil Vaccine That Blunts Opioid-Induced Antinociception and Respiratory Depression. ( Blake, S; Bremer, PT; Ellis, B; Eubanks, LM; Janda, KD; Natori, Y, 2021) |
| " In response to the opioid crisis in NH, Manchester Fire Department (MFD), the state's largest city fire department, launched the Safe Station program in 2016 in partnership with other community organizations." | 1.62 | Implementation of a New Hampshire community-initiated response to the opioid crisis: A mixed-methods process evaluation of Safe Station. ( Bell, K; Marsch, LA; McLeman, B; Meier, A; Metcalf, SA; Moore, SK; Saunders, EC; Walsh, O, 2021) |
| "To assess sedation medication dosage differences between patients with and without opioid use disorder at the time of surgical abortion." | 1.62 | Pain medication requirements in patients with opioid use disorder at the time of surgical abortion: An exploratory study. ( Ramanadhan, S; Srikanth, P; White, KO; Woodhams, E, 2021) |
| "Fentanyl was the most common substance encountered in adult (n = 4656) and pediatric cases (n = 474)." | 1.56 | Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System. ( Darracq, MA; Thornton, SL, 2020) |
| " Further evaluation of naloxone stocking and dosing protocols is needed." | 1.56 | Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl. ( Atti, S; Carpenter, J; Moran, TP; Morgan, B; Murray, BP; Yancey, A, 2020) |
| "To advance the behavioral genetics of prescription opioid abuse, our prior work identified the 129S1/SvlmJ (S1) and related 129P3/J (P3) mouse substrains, respectively, as low and high opioid-taking." | 1.56 | Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains. ( Brewin, LW; Coelho, MA; Ferdousian, S; Gabriella, I; Lieberman, D; Stailey, N; Swauncy, I; Szumlinski, KK; Tran, T, 2020) |
| "Males, and those with existing opioid abuse disorders, are particularly susceptible to death related to NPFD intake." | 1.56 | A deadly trend in fentanyl fatalities (England, 1998-2017). ( Claridge, H; Copeland, CS; Williams, BD, 2020) |
| "Unfortunately, she continued to have withdrawal symptoms despite being optimised to a dose of 32 mg." | 1.56 | High-dose buprenorphine for treatment of high potency opioid use disorder. ( Danilewitz, M; McLean, M, 2020) |
| "Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U." | 1.56 | The protective effect of trusted dealers against opioid overdose in the U.S. ( Carroll, JJ; Green, TC; Rich, JD, 2020) |
| "55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018." | 1.56 | Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. ( Homayra, F; Irvine, M; McGowan, G; Min, JE; Nosyk, B; Pearce, LA; Piske, M; Slaunwhite, A; Zhou, H, 2020) |
| "Fentanyl is a potent synthetic opioid that has contributed to increasing overdose deaths in the United States in recent years." | 1.56 | One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. ( Carroll, JJ; Green, TC; Rich, JD; Stone, AC, 2020) |
| "Fentanyl clearance was defined as the time since last illicit opioid use and the median time between last positive and first negative fentanyl urine screen." | 1.56 | Protracted renal clearance of fentanyl in persons with opioid use disorder. ( Hobelmann, JG; Huhn, AS; Oyler, GA; Strain, EC, 2020) |
| " The arrival of the COVID-19 pandemic comes at time when North America is in the midst of a protracted overdose epidemic caused by a toxic illegal drug supply." | 1.56 | Safer opioid distribution in response to the COVID-19 pandemic. ( Tyndall, M, 2020) |
| "Fentanyl was viewed as pervasive, dangerous, and difficult to avoid in the local drug supply." | 1.56 | Agency in the fentanyl era: Exploring the utility of fentanyl test strips in an opaque drug market. ( Ling, R; Morris, M; Owczarzak, J; Park, JN; Rouhani, S; Sherman, SG; Urquhart, G; Weicker, NP, 2020) |
| "Fentanyl has spread westward, increasing deaths in the short-term and threatening to dramatically worsen the nation's already severe opioid epidemic in the long-term." | 1.56 | Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. ( Cunningham, NJ; Dwyer, CL; Falasinnu, TO; Freedman, RB; Humphreys, K; Santos, NB; Shover, CL; Vest, NA, 2020) |
| "Fentanyl has become widespread in the illicit opioid supply, and is a major driver of overdose mortality." | 1.51 | Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. ( Gryczynski, J; Hill, P; Mitchell, SG; Nichols, H; Schwartz, RP; Wireman, K, 2019) |
| "Fentanyl preference was associated with non-Hispanic white race (adjusted risk ratio (ARR) = 1." | 1.51 | Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. ( Glick, JL; Green, TC; Morales, KB; Park, JN; Rouhani, S; Sherman, SG, 2019) |
| "Carfentanil is a synthetic opioid with an estimated potency that is 10,000 times more than that of morphine and 100 times more than that of fentanyl." | 1.51 | Higher naloxone dosing may be required for opioid overdose. ( Bardsley, R, 2019) |
| "We compared the risk of serious infection among patients initiating long-acting opioid analgesics with and without previously reported immunosuppressive properties." | 1.51 | Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study. ( Greevy, RA; Griffin, MR; Grijalva, CG; Mitchel, EF; Schaffner, W; Stein, CM; Wiese, AD, 2019) |
| " Our program appears to be safe and may serve as a model for other settings dealing with a large numbers of opioid OD." | 1.51 | Safety of a Modified Community Trailer to Manage Patients with Presumed Fentanyl Overdose. ( Ahamad, K; Buxton, J; DeVlaming, S; Grafstein, E; Gustafson, R; Kestler, A; Lysyshyn, M; Prinsloo, G; Scheuermeyer, FX; Van Veen, C, 2019) |
| "Carfentanil was detected in 129 (20%) cases." | 1.51 | Carfentanil-Associated Mortality in Wayne County, Michigan, 2015-2017. ( Aaron, C; Arfken, C; Foley, D; Hlavaty, L; King, A; Sung, L, 2019) |
| "Fentanyl is an important opioid for pain management, but also has exceptional potential for misuse." | 1.51 | Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017. ( Chung, DY; Collins, LK; McCall, KL; Nichols, SD; Pande, LJ; Piper, BJ, 2019) |
| "Clonidine treatment significantly increased fentanyl-vs." | 1.51 | Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. ( Banks, ML; Blake, S; Bremer, PT; Faunce, KE; Hwang, CS; Janda, KD; Natori, Y; Townsend, EA; Zhou, B, 2019) |
| "The fentanyls encountered were carfentanil (N = 17), fentanyl (9), carfentanil and fentanyl together (12), and fentanyl, carfentanil, 4-fluorobutyrylfentanyl, and butyrylfentanyl together (2)." | 1.51 | Detection of fentanyl and fentanyl analogues in biological samples using liquid chromatography-high resolution mass spectrometry. ( Flanagan, RJ; Hudson, S; Rab, E, 2019) |
| "Sensitivity and specificity were lower for heroin (77." | 1.51 | Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology. ( Carlson, RR; Daniulaityte, R; Juhascik, MP; Sizemore, IE; Strayer, KE, 2019) |
| "Fentanyl is a potent synthetic opioid with a variety of possible applications." | 1.51 | Fatal misuse of transdermal fentanyl patches. ( Doberentz, E; Geile, J; Kraemer, M; Maas, A; Madea, B, 2019) |
| "Fentanyl is a highly potent synthetic opioid with rapid onset and significantly higher risk of overdose compared with other opioids." | 1.48 | Intravenous fentanyl use among people who inject drugs in Australia. ( Geddes, L; Iversen, J; Maher, L; Memedovic, S, 2018) |
| "Fentanyl samples were analyzed for other drug content." | 1.48 | Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis. ( Baldwin, N; Buxton, JA; Goel, A; Gray, R; Rieb, LM; Wood, E, 2018) |
| "Carfentanil is an ultra-potent opioid requiring a method with adequate sensitivity for detection in blood specimens from impairment cases." | 1.48 | Carfentanil in Impaired Driving Cases and the Importance of Drug Seizure Data. ( Alford, I; Tiscione, NB, 2018) |
| "Muscle rigidity was the most common atypical presentation, observed in 240 (15." | 1.48 | Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada. ( Gauthier, T; Kinshella, MW; Lysyshyn, M, 2018) |
| "Fentanyl is a frequently used concomitant drug." | 1.46 | High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance Treatment. ( Adam, R; Al-Iassin, J; Canolli, M; Koller, G; Krause, D; Martin, G; Musselmann, R; Plörer, D; Pogarell, O; Schäfer, F; Walcher, S; Winter, C, 2017) |
| "Fentanyl was commonly detected during this period with some clients having multiple fentanyl-positive UDS." | 1.46 | Characterizing fentanyl use in methadone-maintained clients. ( Arfken, CL; Greenwald, MK; Suchanek, J, 2017) |
| "Diffuse alveolar hemorrhage is a rare complication of fentanyl overdose." | 1.43 | Intranasal Fentanyl Intoxication Leading to Diffuse Alveolar Hemorrhage. ( Dunham, M; Ruzycki, S; Sadrzadeh, H; Tremblay, A; Yarema, M, 2016) |
| "A man who had a history of intravenous drug abuse was found unresponsive on the bathroom floor of his home." | 1.43 | An Acute Butyr-Fentanyl Fatality: A Case Report with Postmortem Concentrations. ( Gary, RD; McIntyre, IM; Mena, O; Trochta, A; Wright, J, 2016) |
| "Fentanyl is a synthetic opioid 50-100 times more potent than morphine (2)." | 1.43 | Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014. ( Gladden, RM; Martinez, P; Seth, P, 2016) |
| "Fentanyl is a potent opioid analgesic used in the treatment of pain." | 1.42 | The Fentanyl Patch Boil-Up - A Novel Method of Opioid Abuse. ( Reynolds, TM; Schauer, CK; Shand, JA, 2015) |
| "Fentanyl is a synthetic opioid analgesic historically used as a pain reliever and an anaesthetic." | 1.42 | Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. ( Denissov, G; Giraudon, I; Griffiths, P; Mounteney, J, 2015) |
| "Pyomyositis is etiologically attributed to an infection and predominantly affects large limb or trunk muscles." | 1.39 | Drugs, muscle pallor, and pyomyositis. ( Kubat, B, 2013) |
| "At autopsy, pulmonary edema was the most frequently encountered finding for both groups (77 %)." | 1.39 | Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006). ( Algren, DA; Belson, M; Hepler, BR; Miller, CE; Monteilh, CP; Patel, M; Paulozzi, LJ; Punja, M; Rubin, C; Schier, JG; Schmidt, CJ; Straetemans, M, 2013) |
| "Uncontrolled prescription for non-cancer pain must be criticized due to the problem of addiction." | 1.39 | [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society]. ( Heuser-Grannemann, E; Junker, U; Schenk, M; Wiese, CH; Wirz, S; Zimmermann, M, 2013) |
| "Opioid abuse is common in the United States and is currently on the rise." | 1.38 | Recurrent respiratory depression associated with fentanyl transdermal patch gel reservoir ingestion. ( D'Orazio, JL; Fischel, JA, 2012) |
| "Fentanyl is a potent synthetic opioid with large abuse potential." | 1.38 | Whole fentanyl patch ingestion: a multi-center case series. ( Brooks, DE; Duback-Morris, LF; Feuchter, AC; Katz, KD; Krenzelok, EP; Mrvos, R, 2012) |
| "The Food and Drug Administration approved a single shared Risk Evaluation Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl dosage forms in December 2011." | 1.38 | Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms. ( , 2012) |
| "Methadone poisonings were associated with accidental overdoses with the drug concentration in blood remaining within a therapeutic range." | 1.38 | Comparison of fatal poisonings by prescription opioids. ( Häkkinen, M; Launiainen, T; Ojanperä, I; Vuori, E, 2012) |
| "Fentanyl is an increasingly common drug of abuse." | 1.36 | The prevalence of fentanyl in drug-related deaths in Philadelphia 2004-2006. ( Curtis, JA; Drake, R; Mundy, L; Wingert, WE; Wong, SC, 2010) |
| "Naloxone was administered during 47." | 1.35 | Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. ( Denton, JS; Erickson, T; Schumann, H; Thompson, TM; Zautcke, JL, 2008) |
| "Inflated rates of opioid addiction among anesthesiologists may be caused by chronic exposure to low doses of aerosolized anesthetic/analgesic agents in the operating room." | 1.35 | Fentanyl and propofol exposure in the operating room: sensitization hypotheses and further data. ( Fitzgerald, K; Gold, MS; Goldberger, BA; Kolodner, D; Merlo, LJ, 2008) |
| "When agmatine was administered after fentanyl self-administration had been established (day 8) it had no attenuating effects on bar pressing." | 1.35 | Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration. ( Domingo, KM; Fairbanks, CA; Kitto, KF; Schuster, DJ; Wade, CL, 2008) |
| "When opioids are used for postoperative pain control, it is useful to define the dose-response relationship for analgesia and respiratory depression." | 1.33 | Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. ( Davis, JJ; Dillon, JD; Egan, TD; Hall, RH; Johnson, KB; Niu, SY; Pace, NL; Swenson, JD, 2005) |
| "Fentanyl and saline were chronically administered via minipumps." | 1.33 | Severe deficit in brain reward function associated with fentanyl withdrawal in rats. ( Bajpai, LK; Bruijnzeel, AW; Dennis, DM; Gold, M; Lewis, B; Morey, TE, 2006) |
| "Opiate abuse was greater in anesthesiologists and surgeons compared to other specialties." | 1.33 | Second-hand exposure to aerosolized intravenous anesthetics propofol and fentanyl may cause sensitization and subsequent opiate addiction among anesthesiologists and surgeons. ( Bajpai, L; Cendán, JC; Frost-Pineda, K; Gold, MS; Goldberger, BA; McAuliffe, PF; Melker, RJ; Merves, ML; Pomm, RM, 2006) |
| "Fentanyl is a very strong opioid with analgesic properties that are approximately 80 times stronger than those of morphine and therefore is used in major surgery and treatment of pain in tumor patients." | 1.31 | Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. ( Käferstein, H; Sticht, G, 2000) |
| "Fentanyl is a potent, short-acting narcotic analgesic widely used as a surgical anesthetic and for the control of pain when administered in the form of a transdermal patch." | 1.31 | Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases. ( Anderson, DT; Muto, JJ, 2000) |
| "The results indicate that opioid dependence and tolerance do not develop in parallel." | 1.28 | [Opioid dependence and tolerance in the guinea-pig ileum in vitro]. ( Chen, JQ; Chi, ZQ; Jin, WQ, 1990) |
| ") either prior to chronic administration of an opioid or after opioid dependence had been established." | 1.27 | Opioid dependence prevents the action of pertussis toxin in the guinea-pig myenteric plexus. ( Lux, B; Schulz, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (1.43) | 18.7374 |
| 1990's | 5 (1.19) | 18.2507 |
| 2000's | 39 (9.31) | 29.6817 |
| 2010's | 191 (45.58) | 24.3611 |
| 2020's | 178 (42.48) | 2.80 |
| Authors | Studies |
|---|---|
| Toll, L | 1 |
| Berzetei-Gurske, IP | 1 |
| Polgar, WE | 1 |
| Brandt, SR | 1 |
| Adapa, ID | 1 |
| Rodriguez, L | 1 |
| Schwartz, RW | 1 |
| Haggart, D | 1 |
| O'Brien, A | 1 |
| White, A | 1 |
| Kennedy, JM | 1 |
| Craymer, K | 1 |
| Farrington, L | 1 |
| Auh, JS | 1 |
| Jenkins, RA | 1 |
| Saloner, B | 2 |
| Whitley, P | 2 |
| LaRue, L | 1 |
| Dawson, E | 2 |
| Huskey, A | 1 |
| Young, S | 4 |
| Hayashi, K | 2 |
| Grant, C | 2 |
| Milloy, MJ | 2 |
| DeBeck, K | 2 |
| Wood, E | 6 |
| Fairbairn, N | 6 |
| Cook-Sather, SD | 1 |
| Urban, E | 1 |
| Romano, VA | 1 |
| Romano, MA | 1 |
| Cook, RR | 1 |
| Torralva, R | 1 |
| King, C | 1 |
| Lum, PJ | 1 |
| Tookes, H | 1 |
| Foot, C | 1 |
| Vergara-Rodriguez, P | 1 |
| Rodriguez, A | 1 |
| Fanucchi, L | 1 |
| Lucas, GM | 1 |
| Waddell, EN | 1 |
| Korthuis, PT | 3 |
| Daniulaityte, R | 5 |
| Silverstein, SM | 3 |
| Getz, K | 2 |
| Juhascik, M | 1 |
| McElhinny, M | 1 |
| Dudley, S | 1 |
| Krausz, RM | 2 |
| Westenberg, JN | 2 |
| Vogel, M | 1 |
| Shearer, D | 1 |
| Brar, R | 4 |
| Merkel, R | 1 |
| Moreno, A | 1 |
| Zhang, Y | 1 |
| Herman, R | 1 |
| Ben Nathan, J | 1 |
| Zeb, S | 1 |
| Rahematpura, S | 1 |
| Stecyk, K | 1 |
| Milliken, BT | 1 |
| Hayes, MR | 1 |
| Doyle, RP | 1 |
| Schmidt, HD | 1 |
| Roberts, P | 1 |
| Glowczewski, J | 1 |
| Wise, C | 1 |
| Jiang, X | 1 |
| Guy, GP | 2 |
| Dunphy, C | 2 |
| Pickens, CM | 1 |
| Jones, CM | 3 |
| Ton, E | 1 |
| Stevens, C | 1 |
| Moorman, P | 1 |
| Markey, M | 1 |
| Hunter, B | 1 |
| Bush, R | 1 |
| Jones, P | 1 |
| Niles, JK | 2 |
| Gudin, J | 2 |
| Vivolo-Kantor, AM | 1 |
| Gladden, RM | 3 |
| Mustaquim, D | 1 |
| Seth, P | 3 |
| Kaufman, HW | 2 |
| Chan, CA | 1 |
| Canver, B | 1 |
| McNeil, R | 2 |
| Sue, KL | 1 |
| Peterkin, A | 1 |
| Laks, J | 1 |
| Weinstein, ZM | 2 |
| King, CA | 1 |
| Cook, R | 1 |
| Wheelock, H | 1 |
| Leahy, JM | 2 |
| Goff, A | 1 |
| Morris, CD | 1 |
| Englander, H | 1 |
| Yeo, Y | 1 |
| Johnson, R | 1 |
| Heng, C | 1 |
| Daoust, R | 1 |
| Paquet, J | 1 |
| Huard, V | 1 |
| Chauny, JM | 1 |
| Lavigne, G | 1 |
| Williamson, D | 1 |
| Choinière, M | 1 |
| Lang, E | 1 |
| Yan, JW | 1 |
| Perry, JJ | 1 |
| Emond, M | 1 |
| Gosselin, S | 2 |
| Cournoyer, A | 1 |
| Moss, LM | 1 |
| Algera, MH | 2 |
| Dobbins, R | 1 |
| Gray, F | 1 |
| Strafford, S | 1 |
| Heath, A | 1 |
| van Velzen, M | 2 |
| Heuberger, JAAC | 1 |
| Niesters, M | 2 |
| Olofsen, E | 2 |
| Laffont, CM | 2 |
| Dahan, A | 3 |
| Groeneveld, GJ | 2 |
| Morris, NP | 1 |
| Kaplowitz, E | 1 |
| Macmadu, A | 3 |
| Green, TC | 12 |
| Berk, J | 2 |
| Rich, JD | 5 |
| Brinkley-Rubinstein, L | 3 |
| O'Brien, C | 1 |
| Vemireddy, R | 1 |
| Mohammed, U | 1 |
| Barker, DJ | 1 |
| Lam, T | 1 |
| Barratt, MJ | 1 |
| Bartlett, M | 1 |
| Latimer, J | 1 |
| Jauncey, M | 1 |
| Hiley, S | 1 |
| Clark, N | 1 |
| Gerostamoulos, D | 2 |
| Glowacki, L | 1 |
| Roux, C | 1 |
| Morelato, M | 1 |
| Nielsen, S | 1 |
| Delaney, SR | 1 |
| Tacker, DH | 1 |
| Snozek, CLH | 1 |
| Withey, SL | 1 |
| Cao, L | 2 |
| de Moura, FB | 1 |
| Cayetano, KR | 1 |
| Rohan, ML | 1 |
| Bergman, J | 1 |
| Kohut, SJ | 1 |
| Cole, S | 1 |
| Wirkus, S | 1 |
| Cristiano, N | 1 |
| Thakrar, AP | 1 |
| Kleinman, RA | 1 |
| Alías-Ferri, M | 1 |
| Marchei, E | 1 |
| Pacifici, R | 1 |
| Pichini, S | 1 |
| Pellegrini, M | 1 |
| Pérez-Mañá, C | 1 |
| Papaseit, E | 1 |
| Muga, R | 1 |
| Fonseca, F | 1 |
| Farré, M | 1 |
| Torrens, M | 1 |
| Azar, P | 3 |
| Ignaszewski, MJ | 1 |
| Wong, JSH | 1 |
| Isac, G | 1 |
| Mathew, N | 1 |
| Taylor, M | 1 |
| Pradhan, A | 1 |
| Ogando, YM | 1 |
| Shaya, F | 1 |
| Jegede, O | 1 |
| Parida, S | 1 |
| De Aquino, JP | 1 |
| Jones, AA | 1 |
| Schneider, KE | 1 |
| Mahlobo, CT | 1 |
| Maggs, JL | 1 |
| Dayton, L | 2 |
| Tobin, KE | 2 |
| Latkin, CA | 2 |
| Shorter, GW | 1 |
| Harris, M | 2 |
| McAuley, A | 1 |
| Trayner, KM | 1 |
| Stevens, A | 1 |
| Han, Y | 2 |
| Yuan, K | 2 |
| Shi, J | 1 |
| Yan, W | 2 |
| Lu, L | 2 |
| Weitzman, ER | 1 |
| Kossowsky, J | 1 |
| Blakemore, LM | 1 |
| Cox, R | 1 |
| Dowling, DJ | 1 |
| Levy, O | 1 |
| Needles, EW | 1 |
| Levy, S | 1 |
| Sarker, A | 1 |
| Al-Garadi, MA | 1 |
| Ge, Y | 1 |
| Nataraj, N | 1 |
| Sumner, SA | 2 |
| Rivera, AV | 1 |
| Nolan, ML | 1 |
| Paone, D | 2 |
| Carrillo, SA | 1 |
| Braunstein, SL | 1 |
| Strickland, JC | 2 |
| Marks, KR | 1 |
| Smith, KE | 1 |
| Ellis, JD | 1 |
| Hobelmann, JG | 2 |
| Huhn, AS | 3 |
| Kacha-Ochana, A | 1 |
| Green, JL | 2 |
| Govoni, TD | 1 |
| Robbins, RS | 1 |
| Socias, ME | 3 |
| Le Foll, B | 1 |
| Lim, R | 1 |
| Choi, JC | 1 |
| Mok, WY | 1 |
| Bruneau, J | 1 |
| Rehm, J | 2 |
| Wild, TC | 1 |
| Bozinoff, N | 1 |
| Hassan, A | 2 |
| Jutras-Aswad, D | 1 |
| Jablonski, LA | 1 |
| Bodnar, AR | 1 |
| Stewart, RW | 1 |
| Shin, SS | 1 |
| LaForge, K | 1 |
| Stack, E | 1 |
| Pope, J | 1 |
| Leichtling, G | 1 |
| Larsen, JE | 1 |
| Seaman, A | 1 |
| Hoover, D | 1 |
| Chisholm, L | 1 |
| Blazes, C | 1 |
| Baker, R | 2 |
| Byers, M | 1 |
| Branson, K | 1 |
| Dickson-Gomez, J | 1 |
| Krechel, S | 1 |
| Spector, A | 1 |
| Weeks, M | 1 |
| Ohlrich, J | 1 |
| Green Montaque, HD | 1 |
| Li, J | 1 |
| Kilmer, B | 3 |
| Pardo, B | 4 |
| Caulkins, JP | 1 |
| Reuter, P | 3 |
| Buresh, M | 3 |
| Nahvi, S | 1 |
| Steiger, S | 1 |
| Coffin, PO | 4 |
| McMahan, VM | 1 |
| Murphy, C | 1 |
| Townsend, EA | 5 |
| Blough, BE | 1 |
| Epstein, DH | 1 |
| Negus, SS | 4 |
| Shaham, Y | 3 |
| Banks, ML | 4 |
| Greenwald, MK | 2 |
| Herring, AA | 1 |
| Perrone, J | 1 |
| Nelson, LS | 3 |
| Bublak, R | 1 |
| Patzer, KH | 1 |
| Foltin, RW | 1 |
| Zale, S | 1 |
| Sykes, KA | 1 |
| Nagaraj, N | 1 |
| Scranton, RE | 1 |
| Comer, SD | 4 |
| Ritchie, K | 1 |
| Ghosh, SM | 1 |
| Urbanik, LA | 1 |
| Acharya, NK | 1 |
| Grigson, PS | 1 |
| Racha, S | 1 |
| Fingerhood, M | 1 |
| Hermans, SP | 1 |
| Samiec, J | 1 |
| Golec, A | 1 |
| Trimble, C | 1 |
| Teater, J | 1 |
| Hall, OT | 1 |
| Hochstatter, KR | 1 |
| Terplan, M | 1 |
| Mitchell, SG | 2 |
| Schwartz, RP | 2 |
| Dusek, K | 1 |
| Wireman, K | 2 |
| Gryczynski, J | 2 |
| Lynch, WJ | 3 |
| Bakhti-Suroosh, A | 2 |
| Abel, JM | 1 |
| Filteau, MR | 1 |
| Green, B | 1 |
| Kim, F | 1 |
| McBride, KA | 1 |
| St Onge, CM | 1 |
| Taylor, KM | 1 |
| Marcus, MM | 1 |
| Wang, C | 1 |
| Lassi, N | 1 |
| Robert, M | 1 |
| Jouanjus, E | 1 |
| Khouri, C | 1 |
| Fouilhé Sam-Laï, N | 1 |
| Revol, B | 1 |
| Abadie, R | 3 |
| Cano, M | 3 |
| Habecker, P | 3 |
| Gelpí-Acosta, C | 3 |
| Luba, R | 3 |
| Jones, J | 3 |
| Choi, CJ | 3 |
| Comer, S | 4 |
| Tanz, LJ | 2 |
| Dinwiddie, AT | 2 |
| Mattson, CL | 2 |
| O'Donnell, J | 3 |
| Davis, NL | 2 |
| Slivicki, RA | 1 |
| Earnest, T | 1 |
| Chang, YH | 1 |
| Pareta, R | 1 |
| Casey, E | 1 |
| Li, JN | 1 |
| Tooley, J | 1 |
| Abiraman, K | 1 |
| Vachez, YM | 1 |
| Wolf, DK | 1 |
| Sackey, JT | 1 |
| Kumar Pitchai, D | 1 |
| Moore, T | 1 |
| Gereau, RW | 1 |
| Copits, BA | 1 |
| Kravitz, AV | 1 |
| Creed, MC | 1 |
| Ren, M | 1 |
| Lotfipour, S | 1 |
| Button, L | 1 |
| Williams, AS | 1 |
| Lamparter, C | 1 |
| Woodall, KL | 2 |
| Leitz, SJ | 1 |
| Bagley, SM | 1 |
| Cook, AJ | 1 |
| Jones, C | 1 |
| Lawrence, D | 1 |
| Pearce, P | 1 |
| Jurecka, CA | 1 |
| Barocas, JA | 2 |
| Carpenedo Mun, C | 1 |
| Schuler, H | 1 |
| Byrne, F | 1 |
| Bresani, E | 1 |
| Meyers, K | 1 |
| Dai, Z | 1 |
| Limen, GN | 1 |
| Abate, MA | 1 |
| Kraner, JC | 1 |
| Mock, AR | 1 |
| Smith, GS | 1 |
| Nahhas, RW | 1 |
| Silverstein, S | 1 |
| Martins, S | 1 |
| Carlson, RG | 2 |
| Towers, EB | 2 |
| Setaro, B | 1 |
| Ota, A | 1 |
| Kurata, S | 1 |
| Tatsuma, K | 1 |
| Isaka, H | 1 |
| Higuchi, Y | 1 |
| Nishina, T | 1 |
| Haraguchi, K | 1 |
| Takaki, J | 1 |
| Kihara, T | 1 |
| Tanaka, T | 1 |
| Amagata, T | 1 |
| Inaba, I | 1 |
| Kawashiri, T | 1 |
| Kobayashi, D | 1 |
| Shimazoe, T | 1 |
| Breland, H | 1 |
| Larkins, S | 1 |
| Antonini, V | 1 |
| Freese, T | 1 |
| McGovern, M | 1 |
| Dunn, J | 1 |
| Rawson, R | 1 |
| Shapira, B | 1 |
| Berkovitz, R | 1 |
| Haklai, Z | 1 |
| Goldberger, N | 1 |
| Lipshitz, I | 1 |
| Rosca, P | 1 |
| Barattini, AE | 1 |
| Montanari, C | 1 |
| Edwards, KN | 1 |
| Edwards, S | 1 |
| Gilpin, NW | 1 |
| Pahng, AR | 1 |
| Li, G | 1 |
| Yue, S | 1 |
| Wang, Y | 2 |
| Singh, A | 1 |
| Wang, ZJ | 1 |
| Bell, LA | 1 |
| Hadland, SE | 3 |
| Andraka-Christou, B | 1 |
| Evans, MD | 1 |
| Tranen, B | 1 |
| Mendoza, NS | 1 |
| Allen, C | 1 |
| Arredondo, C | 1 |
| Dunham, R | 1 |
| Fishman, M | 1 |
| Lev, L | 1 |
| Mace, S | 1 |
| Parks, J | 1 |
| Rosa, D | 1 |
| Shoyinka, S | 1 |
| White, D | 1 |
| Williams, A | 1 |
| Gaither, JR | 1 |
| Passik, S | 1 |
| Gordon, AJ | 1 |
| Stein, BD | 1 |
| Bedard, ML | 1 |
| Nowlan, AC | 1 |
| Martin Del Campo, Z | 1 |
| Miller, C | 1 |
| Dasgupta, N | 1 |
| McElligott, ZA | 1 |
| Butler, A | 1 |
| Croxford, R | 1 |
| Bodkin, C | 1 |
| Akbari, H | 1 |
| Bayoumi, AM | 1 |
| Bondy, SJ | 1 |
| Guenter, D | 1 |
| McLeod, KE | 1 |
| Gomes, T | 3 |
| Kanagalingam, T | 1 |
| Kiefer, LA | 1 |
| Orkin, AM | 1 |
| Owusu-Bempah, A | 1 |
| Regenstreif, L | 1 |
| Kouyoumdjian, F | 1 |
| Hughto, JMW | 1 |
| Tapper, A | 1 |
| Rapisarda, SS | 1 |
| Stopka, TJ | 1 |
| Palacios, WR | 1 |
| Case, P | 1 |
| Silcox, J | 1 |
| Moyo, P | 1 |
| Volkow, ND | 2 |
| Blanco, C | 1 |
| Wanar, A | 2 |
| Saia, K | 2 |
| Field, TA | 2 |
| Santa Cruz Mercado, LA | 1 |
| Liu, R | 1 |
| Bharadwaj, KM | 1 |
| Johnson, JJ | 1 |
| Gutierrez, R | 1 |
| Das, P | 1 |
| Balanza, G | 1 |
| Deng, H | 1 |
| Pandit, A | 1 |
| Stone, TAD | 1 |
| Macdonald, T | 1 |
| Horgan, C | 1 |
| Tou, SLJ | 1 |
| Houle, TT | 1 |
| Bittner, EA | 1 |
| Purdon, PL | 1 |
| Salazar, A | 1 |
| Moreno-Pulido, S | 1 |
| Prego-Meleiro, P | 1 |
| Henares-Montiel, J | 1 |
| Pulido, J | 1 |
| Donat, M | 1 |
| Sotres-Fernandez, G | 1 |
| Sordo, L | 1 |
| Terem, A | 1 |
| Fatal, Y | 1 |
| Peretz-Rivlin, N | 1 |
| Turm, H | 1 |
| Koren, SS | 1 |
| Kitsberg, D | 1 |
| Ashwal-Fluss, R | 1 |
| Mukherjee, D | 1 |
| Habib, N | 1 |
| Citri, A | 1 |
| Zawilska, JB | 3 |
| Adamowicz, P | 2 |
| Kurpeta, M | 1 |
| Wojcieszak, J | 1 |
| Kruijtbosch, M | 1 |
| Jansen-Groot Koerkamp, E | 1 |
| van Thiel, G | 1 |
| Numans, M | 1 |
| Heringa, M | 1 |
| Bouvy, M | 1 |
| Carswell, JW | 1 |
| Little, KM | 1 |
| Kosten, TA | 1 |
| Chambers, LC | 1 |
| Hallowell, BD | 1 |
| Zullo, AR | 1 |
| Paiva, TJ | 1 |
| Gaither, R | 1 |
| Hampson, AJ | 1 |
| Beaudoin, FL | 1 |
| Wightman, RS | 1 |
| Savinkina, A | 1 |
| Jurecka, C | 1 |
| Gonsalves, G | 1 |
| Powers, N | 1 |
| Massena, C | 1 |
| Crouse, B | 2 |
| Smith, M | 1 |
| Hicks, L | 1 |
| Evans, JT | 1 |
| Miller, S | 1 |
| Pravetoni, M | 5 |
| Burkhart, D | 1 |
| Ali, SA | 1 |
| Shell, J | 1 |
| Harris, R | 1 |
| Bedder, M | 1 |
| Carvalho, RM | 1 |
| de Magalhães-Barbosa, MC | 1 |
| Bianchi, LM | 1 |
| Rodrigues-Santos, G | 1 |
| da Cunha, AJLA | 1 |
| Bastos, FI | 1 |
| Prata-Barbosa, A | 1 |
| Lane, SM | 1 |
| Jennings, LK | 1 |
| Gainey, SS | 1 |
| Barth, KS | 1 |
| Haynes, L | 1 |
| Moreland, A | 1 |
| Hartwell, K | 1 |
| Brady, KT | 1 |
| Kusic, DM | 1 |
| Heil, J | 1 |
| Zajic, S | 1 |
| Brangan, A | 1 |
| Dairo, O | 1 |
| Heil, S | 1 |
| Feigin, G | 1 |
| Kacinko, S | 1 |
| Buono, RJ | 1 |
| Ferraro, TN | 1 |
| Rafeq, R | 1 |
| Haroz, R | 1 |
| Baston, K | 1 |
| Bodofsky, E | 1 |
| Sabia, M | 1 |
| Salzman, M | 1 |
| Resch, A | 1 |
| Madzo, J | 1 |
| Scheinfeldt, LB | 1 |
| Issa, JJ | 1 |
| Jelinek, J | 1 |
| Hartmann, GE | 1 |
| Sethi, R | 1 |
| Thornton, SL | 1 |
| Darracq, MA | 1 |
| Freni, F | 1 |
| Pezzella, S | 1 |
| Vignali, C | 1 |
| Moretti, M | 1 |
| Cisini, S | 1 |
| Rossetti, C | 1 |
| Ravizza, R | 1 |
| Motta, M | 1 |
| Groppi, A | 1 |
| Morini, L | 1 |
| Greenblatt, DJ | 1 |
| Rosner, B | 1 |
| Neicun, J | 1 |
| Yang, JC | 1 |
| Roman-Urrestarazu, A | 1 |
| Bowen, DA | 1 |
| Carpenter, J | 1 |
| Murray, BP | 1 |
| Atti, S | 1 |
| Moran, TP | 1 |
| Yancey, A | 1 |
| Morgan, B | 1 |
| Bach, H | 1 |
| Jenkins, V | 1 |
| Aledhaim, A | 1 |
| Moayedi, S | 1 |
| Schenkel, SM | 1 |
| Kim, HK | 3 |
| Szumlinski, KK | 3 |
| Coelho, MA | 2 |
| Tran, T | 2 |
| Stailey, N | 1 |
| Lieberman, D | 1 |
| Gabriella, I | 1 |
| Swauncy, I | 1 |
| Brewin, LW | 2 |
| Ferdousian, S | 1 |
| Genberg, BL | 1 |
| Astemborski, J | 1 |
| Kirk, GD | 1 |
| Mehta, SH | 1 |
| Nichols, H | 1 |
| Hill, P | 1 |
| Morales, KB | 3 |
| Park, JN | 6 |
| Glick, JL | 1 |
| Rouhani, S | 4 |
| Sherman, SG | 7 |
| Mojica, MA | 1 |
| Carter, MD | 1 |
| Isenberg, SL | 1 |
| Pirkle, JL | 1 |
| Hamelin, EI | 1 |
| Shaner, RL | 1 |
| Seymour, C | 1 |
| Sheppard, CI | 1 |
| Baldwin, GT | 2 |
| Johnson, RC | 1 |
| Martins, SS | 1 |
| Miller, SC | 1 |
| Salani, D | 1 |
| Mckay, M | 1 |
| Zdanowicz, M | 1 |
| Connery, HS | 1 |
| Taghian, N | 1 |
| Kim, J | 1 |
| Griffin, M | 1 |
| Rockett, IRH | 1 |
| Weiss, RD | 1 |
| Kathryn McHugh, R | 1 |
| Schönfeld, T | 1 |
| Heinemann, A | 1 |
| Schulz, M | 1 |
| Gradl, G | 1 |
| Andresen-Streichert, H | 1 |
| Müller, A | 1 |
| Iwersen-Bergmann, S | 1 |
| Claridge, H | 1 |
| Williams, BD | 1 |
| Copeland, CS | 1 |
| Bardsley, R | 1 |
| Tuazon, E | 1 |
| Kunins, HV | 1 |
| Allen, B | 1 |
| Zibbell, JE | 3 |
| Aldridge, AP | 1 |
| Cauchon, D | 1 |
| DeFiore-Hyrmer, J | 1 |
| Conway, KP | 1 |
| Thomas, I | 1 |
| Roxburgh, A | 3 |
| Hall, WD | 2 |
| Gisev, N | 2 |
| Degenhardt, L | 3 |
| Bardwell, G | 1 |
| Zheng, Y | 1 |
| Khan, MZ | 1 |
| Lambdin, BH | 1 |
| Bluthenthal, RN | 1 |
| Wenger, L | 1 |
| Simpson, K | 1 |
| Kral, AH | 2 |
| Singh, VM | 1 |
| Browne, T | 1 |
| Montgomery, J | 1 |
| Victor, GA | 1 |
| Irvine, MA | 1 |
| McGowan, R | 1 |
| Hammond, K | 1 |
| Davison, C | 1 |
| Coombs, D | 1 |
| Gilbert, M | 2 |
| Danilewitz, M | 1 |
| McLean, M | 1 |
| Wilde, M | 1 |
| Sommer, MJ | 1 |
| Auwärter, V | 1 |
| Hermanns-Clausen, M | 1 |
| McAdam, M | 1 |
| Gummin, DD | 1 |
| Andersson, L | 1 |
| Håkansson, A | 1 |
| Krantz, P | 1 |
| Johnson, B | 1 |
| Ramírez Fernández, MDM | 1 |
| Wille, SMR | 1 |
| Jankowski, D | 1 |
| Hill, V | 1 |
| Samyn, N | 1 |
| McKenzie, M | 2 |
| Struth, E | 1 |
| Lucas, R | 1 |
| Clarke, W | 1 |
| Karamouzian, M | 3 |
| Papamihali, K | 1 |
| Graham, B | 1 |
| Crabtree, A | 2 |
| Mill, C | 1 |
| Kuo, M | 2 |
| Buxton, JA | 5 |
| Chiu, SK | 1 |
| Li, JF | 1 |
| Nolte, KB | 1 |
| Reiner, DJ | 2 |
| Lofaro, OM | 1 |
| Applebey, SV | 2 |
| Korah, H | 1 |
| Venniro, M | 1 |
| Cifani, C | 1 |
| Bossert, JM | 1 |
| Bromley, LA | 1 |
| Nowinski Konchak, J | 1 |
| McGurk, K | 1 |
| Hinami, K | 1 |
| Vacchiano, M | 1 |
| Aks, S | 1 |
| Carroll, JJ | 3 |
| Davis, MP | 1 |
| Behm, B | 1 |
| Meacham, MC | 1 |
| Lynch, KL | 2 |
| Wade, A | 1 |
| Wheeler, E | 2 |
| Riley, ED | 1 |
| Dong, H | 1 |
| Bach, P | 1 |
| Murphy, SM | 1 |
| Pearce, LA | 1 |
| Min, JE | 1 |
| Piske, M | 1 |
| Zhou, H | 1 |
| Homayra, F | 1 |
| Slaunwhite, A | 1 |
| Irvine, M | 1 |
| McGowan, G | 1 |
| Nosyk, B | 1 |
| Antoine, D | 1 |
| Strain, EC | 2 |
| Turner, G | 1 |
| Jardot, J | 1 |
| Hammond, AS | 1 |
| Dunn, KE | 1 |
| Stone, AC | 1 |
| van Amsterdam, J | 1 |
| Pierce, M | 1 |
| van den Brink, W | 1 |
| Oyler, GA | 1 |
| Arrieta Loitegui, M | 1 |
| Caro Teller, JM | 1 |
| Rosas Espinoza, C | 1 |
| Ferrari Piquero, JM | 1 |
| Tyndall, M | 1 |
| Weicker, NP | 1 |
| Owczarzak, J | 1 |
| Urquhart, G | 1 |
| Ling, R | 1 |
| Morris, M | 1 |
| Martinez, S | 1 |
| Jones, JD | 1 |
| Brandt, L | 1 |
| Campbell, ANC | 1 |
| Abbott, R | 1 |
| Moussawi, K | 1 |
| Ortiz, MM | 1 |
| Gantz, SC | 1 |
| Tunstall, BJ | 2 |
| Marchette, RCN | 1 |
| Bonci, A | 1 |
| Koob, GF | 2 |
| Vendruscolo, LF | 3 |
| Moss, L | 1 |
| Dobbins, RL | 1 |
| Heuberger, J | 1 |
| Mistler, CB | 1 |
| Chandra, DK | 1 |
| Copenhaver, MM | 1 |
| Wickersham, JA | 1 |
| Shrestha, R | 1 |
| Radcliff, J | 1 |
| Shover, CL | 1 |
| Falasinnu, TO | 1 |
| Dwyer, CL | 1 |
| Santos, NB | 1 |
| Cunningham, NJ | 1 |
| Freedman, RB | 1 |
| Vest, NA | 1 |
| Humphreys, K | 1 |
| Bryant, CD | 1 |
| Healy, AF | 2 |
| Ruan, QT | 1 |
| Coehlo, MA | 1 |
| Lustig, E | 1 |
| Yazdani, N | 1 |
| Luttik, KP | 1 |
| Swancy, I | 1 |
| Chen, MM | 1 |
| Yung, F | 1 |
| Herath, J | 1 |
| Robinson, C | 1 |
| Gradinati, V | 1 |
| Hamid, F | 1 |
| Baehr, C | 1 |
| Averick, S | 1 |
| Kovaliov, M | 1 |
| Harris, D | 1 |
| Runyon, S | 1 |
| Baruffaldi, F | 2 |
| LeSage, M | 1 |
| May, T | 1 |
| Buhociu, M | 1 |
| Holloway, K | 1 |
| Bremer, PT | 4 |
| Jacob, NT | 1 |
| Janda, KD | 6 |
| Angelini, DJ | 2 |
| Biggs, TD | 2 |
| Prugh, AM | 1 |
| Smith, JA | 1 |
| Hanburger, JA | 1 |
| Llano, B | 1 |
| Avelar, R | 1 |
| Ellis, A | 1 |
| Lusk, B | 1 |
| Malik Naanaa, A | 1 |
| Sisco, E | 2 |
| Sekowski, JW | 2 |
| Connors, NJ | 2 |
| Mazer-Amirshahi, M | 1 |
| Motov, S | 1 |
| Blake, S | 3 |
| Zhou, B | 4 |
| Petrovsky, N | 1 |
| Smith, LC | 2 |
| Hwang, CS | 3 |
| Bergh, MS | 1 |
| Øiestad, ÅML | 1 |
| Baumann, MH | 1 |
| Bogen, IL | 1 |
| DiSalvo, P | 1 |
| Cooper, G | 1 |
| Tsao, J | 1 |
| Romeo, M | 1 |
| Laskowski, LK | 1 |
| Chesney, G | 1 |
| Su, MK | 1 |
| Kosten, TR | 1 |
| Petrakis, IL | 1 |
| Morin, KA | 1 |
| Acharya, S | 1 |
| Eibl, JK | 1 |
| Marsh, DC | 1 |
| Deo, VS | 1 |
| Gilson, TP | 1 |
| Kaspar, C | 1 |
| Singer, ME | 1 |
| Taylor, J | 2 |
| Hulme, S | 1 |
| Bouey, J | 1 |
| Greenfield, V | 1 |
| Zhang, S | 1 |
| Vohra, V | 1 |
| King, AM | 1 |
| Jacobs, E | 1 |
| Aaron, C | 2 |
| Eubanks, LM | 2 |
| Natori, Y | 3 |
| Ellis, B | 3 |
| Wahl, G | 1 |
| Gault, A | 1 |
| Noonan, RK | 2 |
| Kuczyńska, K | 2 |
| Kosmal, W | 1 |
| Markiewicz, K | 1 |
| Caulkins, J | 1 |
| Hodder, SL | 1 |
| Feinberg, J | 1 |
| Strathdee, SA | 1 |
| Shoptaw, S | 1 |
| Altice, FL | 1 |
| Ortenzio, L | 1 |
| Beyrer, C | 1 |
| Lockwood, TE | 1 |
| Vervoordt, A | 1 |
| Lieberman, M | 1 |
| Orihuel, J | 1 |
| Claypool, SM | 1 |
| Zubiago, J | 1 |
| Murphy, M | 1 |
| Guardado, R | 1 |
| Daudelin, D | 1 |
| Patil, D | 1 |
| Wurcel, A | 1 |
| Mackay, L | 1 |
| Kerr, T | 2 |
| Moore, SK | 1 |
| Saunders, EC | 1 |
| McLeman, B | 1 |
| Metcalf, SA | 1 |
| Walsh, O | 1 |
| Bell, K | 1 |
| Meier, A | 1 |
| Marsch, LA | 1 |
| Park, H | 1 |
| Lee, JC | 1 |
| Raleigh, MD | 1 |
| King, SJ | 1 |
| Saykao, A | 1 |
| Hamid, FA | 1 |
| Winston, S | 1 |
| LeSage, MG | 1 |
| Pentel, PR | 1 |
| Mariani, JJ | 1 |
| Mahony, AL | 1 |
| Podell, SC | 1 |
| Brooks, DJ | 1 |
| Brezing, C | 1 |
| Luo, SX | 1 |
| Naqvi, NH | 1 |
| Levin, FR | 1 |
| Ramanadhan, S | 1 |
| Woodhams, E | 1 |
| Srikanth, P | 1 |
| White, KO | 1 |
| Zule, W | 1 |
| Chu, TH | 1 |
| Rueter, M | 1 |
| Palmaro, A | 1 |
| Lapeyre-Mestre, M | 1 |
| Foglia, R | 1 |
| Cooperman, N | 1 |
| Mattern, D | 1 |
| Borys, S | 1 |
| Kline, A | 1 |
| Miller, JM | 1 |
| Stogner, JM | 1 |
| Miller, BL | 1 |
| Blough, S | 1 |
| McLaughlin, K | 1 |
| Krenzelok, EP | 2 |
| Rose, ME | 1 |
| Jimenez, SM | 1 |
| Brown, CN | 1 |
| Kippin, TE | 1 |
| Cicero, TJ | 2 |
| Ellis, MS | 2 |
| Kasper, ZA | 1 |
| Worley, J | 1 |
| Guerrieri, D | 2 |
| Rapp, E | 1 |
| Roman, M | 1 |
| Thelander, G | 1 |
| Kronstrand, R | 2 |
| Dwyer, JB | 1 |
| Janssen, J | 1 |
| Luckasevic, TM | 1 |
| Williams, KE | 1 |
| Walley, AY | 1 |
| Unick, GJ | 1 |
| Ciccarone, D | 4 |
| Beletsky, L | 2 |
| Davis, CS | 1 |
| Ondocsin, J | 1 |
| Mars, SG | 2 |
| Slavova, S | 1 |
| Costich, JF | 1 |
| Bunn, TL | 1 |
| Luu, H | 1 |
| Singleton, M | 1 |
| Hargrove, SL | 1 |
| Triplett, JS | 1 |
| Quesinberry, D | 1 |
| Ralston, W | 1 |
| Ingram, V | 1 |
| Dobbins, T | 1 |
| Burns, L | 2 |
| Pearson, S | 1 |
| Seither, J | 1 |
| Reidy, L | 1 |
| Moss, MJ | 1 |
| Warrick, BJ | 1 |
| McKay, CA | 1 |
| Dubé, PA | 1 |
| Palmer, RB | 2 |
| Stolbach, AI | 1 |
| Cole, JB | 1 |
| Cheng, T | 1 |
| Massey, J | 1 |
| Kilkenny, M | 1 |
| Batdorf, S | 1 |
| Sanders, SK | 1 |
| Ellison, D | 1 |
| Halpin, J | 1 |
| Bixler, D | 1 |
| Haddy, L | 1 |
| Gupta, R | 1 |
| Aschenbrenner, DS | 1 |
| Barry, CL | 1 |
| Papsun, D | 1 |
| Isenschmid, D | 2 |
| Logan, BK | 3 |
| Butler, DC | 1 |
| Shanks, K | 1 |
| Behonick, GS | 1 |
| Smith, D | 1 |
| Presnell, SE | 1 |
| Tormos, LM | 1 |
| Armenian, P | 2 |
| Vo, KT | 1 |
| Barr-Walker, J | 1 |
| Dowell, D | 1 |
| Houry, D | 1 |
| Fischer, B | 3 |
| Vojtila, L | 1 |
| Krotulski, AJ | 1 |
| Papsun, DM | 2 |
| Friscia, M | 1 |
| Swartz, JL | 1 |
| Holsey, BD | 1 |
| Pergolizzi, JV | 1 |
| LeQuang, JA | 1 |
| Taylor, R | 1 |
| Raffa, RB | 1 |
| Duru, UB | 1 |
| Pawar, G | 1 |
| Barash, JA | 1 |
| Miller, LE | 1 |
| Thiruselvam, IK | 1 |
| Haut, MW | 1 |
| Palaty, J | 1 |
| Konforte, D | 1 |
| Karakosta, T | 1 |
| Wong, E | 1 |
| Stefan, C | 1 |
| Geddes, L | 1 |
| Iversen, J | 1 |
| Memedovic, S | 1 |
| Maher, L | 1 |
| Chatterton, CN | 1 |
| Scott-Ham, M | 1 |
| Kenney, SR | 1 |
| Anderson, BJ | 1 |
| Conti, MT | 1 |
| Bailey, GL | 1 |
| Stein, MD | 2 |
| Clarke, J | 1 |
| Marshall, BDL | 3 |
| Alexander-Scott, N | 1 |
| Boss, R | 1 |
| Baldwin, N | 1 |
| Gray, R | 1 |
| Goel, A | 1 |
| Rieb, LM | 1 |
| Ponizovsky, AM | 1 |
| Marom, E | 1 |
| Weizman, A | 1 |
| Schwartzberg, E | 1 |
| Madras, BK | 1 |
| Brockbals, L | 2 |
| Staeheli, SN | 2 |
| Gascho, D | 1 |
| Ebert, LC | 1 |
| Kraemer, T | 2 |
| Steuer, AE | 2 |
| Mema, SC | 1 |
| Sage, C | 1 |
| Popoff, S | 1 |
| Bridgeman, J | 1 |
| Taylor, D | 1 |
| Corneil, T | 1 |
| Angela Parham, M | 1 |
| Pomerleau, AC | 1 |
| Peralta, G | 1 |
| Drenzek, CL | 1 |
| Edison, LS | 1 |
| Ponté, C | 1 |
| Lepelley, M | 1 |
| Boucherie, Q | 1 |
| Mallaret, M | 1 |
| Lapeyre Mestre, M | 1 |
| Pradel, V | 1 |
| Micallef, J | 1 |
| Tiscione, NB | 1 |
| Alford, I | 1 |
| Peterson, BL | 1 |
| Schreiber, S | 1 |
| Fumo, N | 1 |
| Brooke Lerner, E | 1 |
| Ratycz, MC | 1 |
| Papadimos, TJ | 1 |
| Vanderbilt, AA | 1 |
| Gauthier, T | 2 |
| Kinshella, MW | 2 |
| Godwin, J | 1 |
| Rowe, C | 1 |
| Stephen Jones, T | 1 |
| Yeh, C | 1 |
| Fogarty, MF | 1 |
| McGowan, CR | 1 |
| Platt, L | 1 |
| Hope, V | 1 |
| Rhodes, T | 1 |
| Burns, SM | 1 |
| Cunningham, CW | 1 |
| Mercer, SL | 1 |
| Grzonkowski, P | 1 |
| Kacprzak, Ł | 1 |
| Belzak, L | 1 |
| Halverson, J | 1 |
| Avedschmidt, S | 1 |
| Schmidt, C | 1 |
| Kesha, K | 1 |
| Moons, D | 1 |
| Gupta, A | 1 |
| Weir, BW | 1 |
| Allen, ST | 2 |
| Chaulk, P | 1 |
| Bruera, E | 1 |
| Manchikanti, L | 1 |
| Sanapati, J | 1 |
| Benyamin, RM | 1 |
| Atluri, S | 1 |
| Kaye, AD | 1 |
| Hirsch, JA | 1 |
| Chenaf, C | 1 |
| Kaboré, JL | 1 |
| Delorme, J | 1 |
| Pereira, B | 1 |
| Mulliez, A | 1 |
| Zenut, M | 1 |
| Delage, N | 1 |
| Ardid, D | 1 |
| Eschalier, A | 1 |
| Authier, N | 1 |
| Reardon, S | 2 |
| Brimdyr, K | 1 |
| Cadwell, K | 1 |
| Rothberg, RL | 1 |
| Stith, K | 1 |
| McKeown, HE | 1 |
| Rook, TJ | 1 |
| Pearson, JR | 1 |
| Jones, OAH | 1 |
| Dohoo, C | 1 |
| Forsting, S | 1 |
| Lysyshyn, M | 4 |
| Kjellqvist, F | 1 |
| Gréen, H | 1 |
| Bahr, MP | 1 |
| Williams, BA | 1 |
| Wiese, AD | 1 |
| Griffin, MR | 1 |
| Schaffner, W | 1 |
| Stein, CM | 1 |
| Greevy, RA | 1 |
| Mitchel, EF | 1 |
| Grijalva, CG | 1 |
| D'Errico, S | 1 |
| Peiper, NC | 1 |
| Clarke, SD | 1 |
| Vincent, LB | 1 |
| Scheuermeyer, FX | 1 |
| Grafstein, E | 1 |
| Buxton, J | 1 |
| Ahamad, K | 1 |
| DeVlaming, S | 1 |
| Prinsloo, G | 1 |
| Van Veen, C | 1 |
| Kestler, A | 1 |
| Gustafson, R | 1 |
| Krieger, MS | 1 |
| Goedel, WC | 1 |
| Bernstein, E | 1 |
| Laing, MK | 1 |
| Tupper, KW | 2 |
| Christopher, PP | 1 |
| Anderson, B | 1 |
| Nikoo, M | 1 |
| Miles, I | 1 |
| Nellhaus, EM | 1 |
| Murray, S | 1 |
| Hansen, Z | 1 |
| Loudin, S | 1 |
| Davies, TH | 1 |
| Ochalek, TA | 1 |
| Parker, MA | 1 |
| Higgins, ST | 1 |
| Sigmon, SC | 1 |
| Franzén, L | 1 |
| Beck, O | 1 |
| Helander, A | 1 |
| Gentile, S | 1 |
| Schlaepfer, M | 1 |
| Bissig, C | 1 |
| Bolliger, SA | 1 |
| Cahill, CM | 1 |
| Bijral, P | 1 |
| Hayhurst, KP | 1 |
| Bird, SM | 1 |
| Millar, T | 1 |
| King, A | 1 |
| Foley, D | 1 |
| Arfken, C | 1 |
| Sung, L | 1 |
| Hlavaty, L | 1 |
| Abbasi, AB | 1 |
| Salisbury-Afshar, E | 1 |
| Jovanov, D | 1 |
| Berberet, C | 1 |
| Arunkumar, P | 2 |
| Aks, SE | 1 |
| Layden, JE | 1 |
| Pho, MT | 1 |
| Leen, JLS | 1 |
| Juurlink, DN | 2 |
| McLean, K | 1 |
| Monnat, SM | 1 |
| Rigg, K | 1 |
| Sterner, GE | 1 |
| Verdery, A | 1 |
| Berry, MD | 1 |
| Mahikhan, F | 1 |
| Hashemian, M | 1 |
| Dehesh, T | 1 |
| Jafari, E | 1 |
| Jafari, M | 1 |
| Rahimi, HR | 1 |
| Argento, E | 1 |
| Tadrous, M | 1 |
| Greaves, S | 1 |
| Martins, D | 2 |
| Nadeem, K | 1 |
| Singh, S | 2 |
| Mamdani, MM | 1 |
| Collins, LK | 1 |
| Pande, LJ | 1 |
| Chung, DY | 2 |
| Nichols, SD | 2 |
| McCall, KL | 2 |
| Piper, BJ | 2 |
| Davey-Rothwell, MA | 1 |
| Rosenblum, D | 1 |
| Taylor, RG | 1 |
| Budhram, A | 1 |
| Lee, DH | 1 |
| Mirsattari, SM | 1 |
| Strike, C | 1 |
| Watson, TM | 1 |
| Mazer-Amirshahi, ME | 1 |
| Simpson, KJ | 1 |
| Moran, MT | 1 |
| Foster, ML | 1 |
| Shah, DT | 1 |
| Faunce, KE | 1 |
| Rab, E | 1 |
| Flanagan, RJ | 1 |
| Hudson, S | 1 |
| Schepis, TS | 1 |
| McCabe, VV | 1 |
| Boyd, CJ | 1 |
| McCabe, SE | 1 |
| Maughan, MN | 1 |
| Feasel, MG | 1 |
| Peterson, M | 1 |
| Rich, J | 1 |
| Truong, AQ | 1 |
| Pognon, K | 1 |
| Carlson, RR | 1 |
| Juhascik, MP | 1 |
| Strayer, KE | 1 |
| Sizemore, IE | 1 |
| Serinelli, S | 1 |
| White, S | 1 |
| Wang, D | 1 |
| Gitto, L | 1 |
| Cheng, J | 1 |
| Wang, S | 1 |
| Lin, W | 1 |
| Wu, N | 1 |
| Chen, M | 1 |
| Xie, XQ | 1 |
| Feng, Z | 1 |
| Geile, J | 1 |
| Maas, A | 1 |
| Kraemer, M | 1 |
| Doberentz, E | 1 |
| Madea, B | 1 |
| Bucerius, SM | 1 |
| Haggerty, KD | 1 |
| Drummer, OH | 2 |
| Pilgrim, J | 1 |
| Farrell, M | 1 |
| Kubat, B | 1 |
| Collopy, KT | 1 |
| Kivlehan, SM | 1 |
| Snyder, SR | 1 |
| Michel-Lauter, B | 1 |
| Bernardy, K | 1 |
| Schwarzer, A | 1 |
| Nicolas, V | 1 |
| Maier, C | 2 |
| Devine, JW | 1 |
| Trice, S | 1 |
| Nwokeji, E | 1 |
| Yarger, S | 1 |
| Anekwe, TM | 1 |
| Davies, W | 1 |
| Lawrence, J | 1 |
| Passik, SD | 3 |
| Narayana, A | 2 |
| Yang, R | 1 |
| Granata, R | 1 |
| Bossi, P | 1 |
| Bertulli, R | 1 |
| Saita, L | 1 |
| Layton, D | 1 |
| Osborne, V | 1 |
| Al-Shukri, M | 1 |
| Shakir, SA | 1 |
| Moore, PW | 1 |
| Donovan, JW | 1 |
| Wade, CL | 2 |
| Schlosburg, JE | 1 |
| Hernandez, DO | 1 |
| Marinetti, LJ | 1 |
| Ehlers, BJ | 1 |
| Schauer, CK | 1 |
| Shand, JA | 1 |
| Reynolds, TM | 1 |
| Cai, B | 1 |
| Engqvist, H | 1 |
| Bredenberg, S | 1 |
| Ferrari, R | 1 |
| Zanolin, ME | 1 |
| Duse, G | 1 |
| Visentin, M | 1 |
| Mounteney, J | 1 |
| Giraudon, I | 1 |
| Denissov, G | 1 |
| Griffiths, P | 1 |
| Cahill, K | 1 |
| Shehab, RM | 1 |
| Lowney, A | 1 |
| McQuillan, R | 1 |
| Russell, C | 1 |
| Murphy, Y | 1 |
| Kurdyak, P | 1 |
| Ruzycki, S | 2 |
| Yarema, M | 2 |
| Dunham, M | 1 |
| Sadrzadeh, H | 1 |
| Tremblay, A | 1 |
| McIntyre, IM | 1 |
| Trochta, A | 1 |
| Gary, RD | 1 |
| Wright, J | 1 |
| Mena, O | 1 |
| Wiegand, TJ | 1 |
| Le Lait, MC | 1 |
| Bartelson, BB | 1 |
| Dart, RC | 1 |
| Kawai, K | 1 |
| Yoshizawa, K | 1 |
| Fujie, M | 1 |
| Kobayashi, H | 1 |
| Ogawa, Y | 1 |
| Yajima, T | 1 |
| Erbas, B | 1 |
| Arnold, M | 1 |
| Copland, AP | 1 |
| Gaspar, JP | 1 |
| Wang, AY | 1 |
| Olson, A | 1 |
| Anaya, A | 1 |
| Kurtz, A | 1 |
| Ruegner, R | 1 |
| Gerona, RR | 1 |
| Martinez, P | 1 |
| Romualdi, P | 1 |
| Santi, P | 1 |
| Candeletti, S | 1 |
| Fernandes, K | 1 |
| Juurlink, D | 1 |
| Mamdani, M | 1 |
| Paterson, JM | 1 |
| Spooner, L | 1 |
| Ahmad, M | 1 |
| Raza, T | 1 |
| Suzuki, J | 1 |
| El-Haddad, S | 1 |
| Marshall, BD | 1 |
| Krause, D | 1 |
| Plörer, D | 1 |
| Koller, G | 1 |
| Martin, G | 1 |
| Winter, C | 1 |
| Adam, R | 1 |
| Canolli, M | 1 |
| Al-Iassin, J | 1 |
| Musselmann, R | 1 |
| Walcher, S | 1 |
| Schäfer, F | 1 |
| Pogarell, O | 1 |
| Rodda, LN | 1 |
| Pilgrim, JL | 1 |
| Di Rago, M | 1 |
| Crump, K | 1 |
| Frank, RG | 1 |
| Pollack, HA | 1 |
| Arfken, CL | 1 |
| Suchanek, J | 1 |
| Firestone, M | 1 |
| Goldman, B | 1 |
| Schumann, H | 1 |
| Erickson, T | 1 |
| Thompson, TM | 1 |
| Zautcke, JL | 1 |
| Denton, JS | 1 |
| Goicoechea, C | 1 |
| Sánchez, E | 1 |
| Cano, C | 1 |
| Jagerovic, N | 1 |
| Martín, MI | 1 |
| Schrode, K | 1 |
| Stevenson, GW | 1 |
| Merlo, LJ | 1 |
| Goldberger, BA | 3 |
| Kolodner, D | 1 |
| Fitzgerald, K | 1 |
| Gold, MS | 3 |
| Hamunen, K | 1 |
| Paakkari, P | 1 |
| Kalso, E | 1 |
| Sirohi, S | 1 |
| Dighe, SV | 1 |
| Madia, PA | 1 |
| Yoburn, BC | 1 |
| Grewal, PK | 1 |
| Firnhaber-Burgos, JB | 1 |
| Nelson, L | 1 |
| Schwaner, R | 1 |
| Wang, YH | 1 |
| Sun, JF | 1 |
| Tao, YM | 1 |
| Xu, XJ | 1 |
| Chi, ZQ | 3 |
| Liu, JG | 1 |
| Wong, SC | 1 |
| Mundy, L | 1 |
| Drake, R | 1 |
| Curtis, JA | 1 |
| Wingert, WE | 1 |
| Messina, J | 1 |
| Golsorkhi, A | 1 |
| Xie, F | 1 |
| Paradis, A | 1 |
| Ortbal, Z | 1 |
| Stimmel, B | 1 |
| Graham, NA | 1 |
| Law, BF | 1 |
| Hettick, JM | 1 |
| Hornsby-Myers, J | 1 |
| Siegel, PD | 1 |
| Fine, PG | 1 |
| Williams, BS | 1 |
| Wong, D | 1 |
| Amin, S | 1 |
| Mandel, L | 1 |
| Carunchio, MJ | 1 |
| D'Orazio, JL | 1 |
| Fischel, JA | 1 |
| Mrvos, R | 1 |
| Feuchter, AC | 1 |
| Katz, KD | 1 |
| Duback-Morris, LF | 1 |
| Brooks, DE | 1 |
| Elhabazi, K | 1 |
| Trigo, JM | 1 |
| Mollereau, C | 1 |
| Moulédous, L | 1 |
| Zajac, JM | 1 |
| Bihel, F | 1 |
| Schmitt, M | 1 |
| Bourguignon, JJ | 1 |
| Meziane, H | 1 |
| Petit-demoulière, B | 1 |
| Bockel, F | 1 |
| Maldonado, R | 1 |
| Simonin, F | 1 |
| Núñez-Olarte, JM | 1 |
| Alvarez-Jiménez, P | 1 |
| Leclerc-Springer, J | 1 |
| Häkkinen, M | 1 |
| Launiainen, T | 1 |
| Vuori, E | 1 |
| Ojanperä, I | 1 |
| Eastwood, EC | 1 |
| Phillips, TJ | 1 |
| Scharnagel, R | 1 |
| Kaiser, U | 1 |
| Schütze, A | 1 |
| Heineck, R | 1 |
| Gossrau, G | 1 |
| Sabatowski, R | 1 |
| Algren, DA | 1 |
| Monteilh, CP | 1 |
| Punja, M | 1 |
| Schier, JG | 1 |
| Belson, M | 1 |
| Hepler, BR | 1 |
| Schmidt, CJ | 1 |
| Miller, CE | 1 |
| Patel, M | 1 |
| Paulozzi, LJ | 1 |
| Straetemans, M | 1 |
| Rubin, C | 1 |
| Hannon, B | 1 |
| Zimmermann, C | 1 |
| Bryson, JR | 1 |
| Wirz, S | 1 |
| Wiese, CH | 1 |
| Zimmermann, M | 1 |
| Junker, U | 1 |
| Heuser-Grannemann, E | 1 |
| Schenk, M | 1 |
| Liu, ZH | 1 |
| He, Y | 1 |
| Jin, WQ | 2 |
| Chen, XJ | 1 |
| Zhang, HP | 1 |
| Shen, QX | 1 |
| Nevin, J | 1 |
| Swenson, JD | 2 |
| Davis, JJ | 2 |
| Johnson, KB | 2 |
| Vansteensel, MJ | 1 |
| Magnone, MC | 1 |
| van Oosterhout, F | 1 |
| Baeriswyl, S | 1 |
| Albrecht, U | 1 |
| Albus, H | 1 |
| Meijer, JH | 1 |
| Compton, WM | 1 |
| Hall, RH | 1 |
| Dillon, JD | 1 |
| Egan, TD | 1 |
| Pace, NL | 1 |
| Niu, SY | 1 |
| Bruijnzeel, AW | 1 |
| Lewis, B | 1 |
| Bajpai, LK | 1 |
| Morey, TE | 1 |
| Dennis, DM | 1 |
| Gold, M | 1 |
| Skulska, A | 1 |
| Kała, M | 1 |
| Parczewski, A | 1 |
| Jin, M | 1 |
| Gock, SB | 1 |
| Jannetto, PJ | 1 |
| Jentzen, JM | 1 |
| Wong, SH | 1 |
| McAuliffe, PF | 1 |
| Bajpai, L | 1 |
| Merves, ML | 1 |
| Frost-Pineda, K | 1 |
| Pomm, RM | 1 |
| Melker, RJ | 1 |
| Cendán, JC | 1 |
| Katz, NP | 1 |
| Buse, DC | 1 |
| Budman, SH | 1 |
| Wing Venuti, S | 1 |
| Fernandez, KC | 1 |
| Benoit, C | 1 |
| Bianchi, R | 1 |
| Cooper, D | 1 |
| Jasinski, DR | 1 |
| Smith, DE | 1 |
| Butler, SF | 1 |
| Greenwald, M | 1 |
| Johanson, CE | 1 |
| Bueller, J | 1 |
| Chang, Y | 1 |
| Moody, DE | 1 |
| Kilbourn, M | 1 |
| Koeppe, R | 1 |
| Zubieta, JK | 2 |
| Martin, TL | 1 |
| McLellan, BA | 1 |
| Eipe, N | 1 |
| Kay, J | 1 |
| Markman, JD | 1 |
| Fodale, V | 1 |
| Mafrica, F | 1 |
| Santamaria, LB | 1 |
| Coleman, JJ | 1 |
| Schuster, DJ | 1 |
| Domingo, KM | 1 |
| Kitto, KF | 1 |
| Fairbanks, CA | 1 |
| Gorelick, DA | 1 |
| Stauffer, R | 1 |
| Ravert, HT | 1 |
| Dannals, RF | 1 |
| Frost, JJ | 1 |
| Brewer, C | 1 |
| Gastfriend, DR | 2 |
| Connor, DF | 1 |
| Muir, A | 1 |
| Thornton, SR | 1 |
| Lohmann, AB | 1 |
| Nicholson, RA | 1 |
| Smith, FL | 1 |
| Joranson, DE | 1 |
| Ryan, KM | 1 |
| Gilson, AM | 1 |
| Dahl, JL | 1 |
| Käferstein, H | 1 |
| Sticht, G | 1 |
| Anderson, DT | 1 |
| Muto, JJ | 1 |
| Elman, I | 1 |
| D'Ambra, MN | 1 |
| Krause, S | 1 |
| Breiter, H | 1 |
| Kane, M | 1 |
| Morris, R | 1 |
| Tuffy, L | 1 |
| Klein, LC | 1 |
| Yaster, M | 1 |
| Nichols, DG | 1 |
| Burgess, FW | 1 |
| Arvanitis, ML | 1 |
| Satonik, RC | 1 |
| Ostrowsky, BE | 1 |
| Whitener, C | 1 |
| Bredenberg, HK | 1 |
| Carson, LA | 1 |
| Holt, S | 1 |
| Hutwagner, L | 1 |
| Arduino, MJ | 1 |
| Jarvis, WR | 1 |
| Morgan, AD | 1 |
| Campbell, UC | 1 |
| Fons, RD | 1 |
| Carroll, ME | 1 |
| Chen, JQ | 1 |
| Koren, G | 1 |
| Maurice, L | 1 |
| Croughan, J | 1 |
| Sanders, K | 1 |
| Schulz, R | 3 |
| Seidl, E | 1 |
| Herz, A | 1 |
| Lux, B | 2 |
| Hagelsten, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl[NCT06089707] | Phase 3 | 25 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Impact of a Novel HIV Peer Navigation and Overdose Prevention Intervention on Engagement in the HIV Prevention and Treatment Cascade[NCT05977881] | 600 participants (Anticipated) | Interventional | 2023-07-28 | Recruiting | |||
| Pilot Study to Look at Feasibility of Testing and Treatment of Combination Fentanyl and Opioid Dependent Individuals With Different Buprenorphine Induction Methods[NCT04794790] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2022-05-09 | Recruiting | ||
| Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal[NCT05712707] | Phase 1/Phase 2 | 160 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists - a Study in Opioid naïve Individuals and Chronic Opioid Users Under Real-life Conditions[NCT05338632] | Phase 1 | 24 participants (Anticipated) | Interventional | 2022-06-24 | Recruiting | ||
| Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care[NCT01751789] | 335 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Opioid-free Total Hip Arthroplasty: A Randomized Controlled Trial[NCT04421196] | 0 participants (Actual) | Interventional | 2022-09-15 | Withdrawn (stopped due to Currently does not have active IRB status.) | |||
| Optimization of Post-Operative Pain Following Orthognathic Surgery With Personalized Opioid Prescription and Tapering Protocols[NCT05708521] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | ||
| The Effect of Intraoperative Esmolol Administration on Postoperative Recovery and Chronic Pain[NCT05567822] | 70 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | |||
| The Rhode Island Prescription and Illicit Drug Study Responding to Fentanyl and Associated Harms[NCT04372238] | 509 participants (Anticipated) | Interventional | 2020-09-03 | Recruiting | |||
| Consumption of New Psychoactive Substances in Intoxicated Patients During the Winter Activities[NCT04155281] | 87 participants (Actual) | Observational | 2020-01-23 | Completed | |||
| Efficiency And Quality In Post-Surgical Pain Therapy After Discharge[NCT05221866] | 711 participants (Actual) | Interventional | 2022-03-14 | Completed | |||
| Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care[NCT02324933] | Phase 4 | 0 participants (Actual) | Interventional | 2014-08-31 | Withdrawn (stopped due to insufficient population, unable to recruit) | ||
| A Hydromorphone High Resolution Pharmacokinetic-Pharmacodynamic Fingerprint as the Basis for Identifying Sex Differences in Opioid Pharmacokinetics and Pharmacodynamics[NCT01123486] | 0 participants (Actual) | Interventional | 2015-01-31 | Withdrawn (stopped due to PI relocated to new university) | |||
| A Multiple-Dose Study of Blockade of Subjective Opioid Effects, Plasma Levels, and Safety of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Subjects With Opioid Use Disorder[NCT02044094] | Phase 2 | 39 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Effects of Chronic Musculoskeletal Pain and Opioidergic Versus Placebo Interventions on Neuroendocrine Function in Men[NCT00737737] | Phase 4 | 8 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme drug effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 55.64 | 5.23 | 3.69 | 4.85 | 7.76 | 1.46 | 0.69 | 1.64 | 1.94 | 4.51 | 0.06 | 1.94 | 0.98 |
| Hydromorphone 6 mg | 35.77 | 3.01 | 1.01 | 1.74 | 3.98 | 1.56 | 0.20 | -0.09 | -0.97 | -0.22 | -0.16 | 0.13 | 0.24 |
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme sedation 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 27.58 | 4.20 | 3.92 | 3.76 | 5.11 | 1.34 | 2.20 | 1.55 | 1.61 | 4.49 | -0.12 | 2.44 | -0.26 |
| Hydromorphone 6 mg | 11.10 | 2.78 | 0.38 | 0.84 | 2.80 | 1.76 | -0.23 | -0.12 | -0.64 | 0.54 | -0.59 | 0.55 | 2.06 |
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme liking of the drug 30 minutes before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 60.61 | 6.93 | 2.90 | 4.93 | 6.68 | 1.21 | 3.16 | 1.88 | 1.93 | 4.17 | 0.13 | 3.24 | 2.78 |
| Hydromorphone 6 mg | 45.36 | 3.66 | 0.59 | 0.86 | 3.32 | 0.74 | 0.35 | -0.15 | -1.05 | -0.12 | -0.09 | -0.32 | -0.03 |
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme bad effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 6.25 | -0.01 | 0.53 | 0.39 | 0.43 | -0.10 | 0.03 | -0.12 | -0.04 | 0.06 | -0.10 | 0.05 | -0.02 |
| Hydromorphone 6 mg | 2.35 | 0.04 | 0.14 | 0.08 | -0.03 | 0.03 | 0.03 | -0.09 | 0.01 | 0.02 | -0.08 | 0.11 | -0.01 |
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme good effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 58.51 | 5.83 | 3.50 | 6.17 | 7.65 | 1.41 | 0.75 | 1.65 | 1.86 | 4.42 | 0.15 | 2.56 | 1.70 |
| Hydromorphone 6 mg | 40.76 | 3.01 | 0.60 | 1.71 | 4.03 | 1.40 | 0.35 | -0.07 | -1.10 | -0.13 | 0.03 | -0.13 | 0.13 |
"Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme high from the drug 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo. For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: mean predicted mu opioid receptor occupancy 6 mg / 18 mg" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 50.94 | 4.85 | 3.15 | 4.37 | 7.14 | 1.44 | 2.09 | 1.82 | 1.85 | 4.02 | -0.02 | 1.51 | 0.71 |
| Hydromorphone 6 mg | 30.40 | 3.06 | 0.52 | 1.67 | 3.66 | 1.55 | 0.42 | -0.12 | -1.17 | -0.25 | -0.23 | 0.04 | 0.17 |
"The study's primary objective was to determine if the opioid blocking effect for the first injection of buprenorphine 300 mg (RBP-6000) on Day 1 was not inferior to placebo when challenged by hydromorphone.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme liking of the drug 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone administration on the challenge days listed in the time frame field. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis." (NCT02044094)
Timeframe: Weeks 1 (Days 5-7), 2 (Days 12-14), 3 (Days 19-21), 4 (Days 26-28)
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Hydromorphone 18 mg | 8.374 | 4.750 | 6.246 | 7.211 |
| Hydromorphone 6 mg | 5.103 | 2.436 | 2.183 | 3.849 |
| Placebo | 1.447 | 1.850 | 1.320 | 0.534 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme drug effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 58.912 | 6.433 | 5.466 | 6.046 | 8.269 | 2.388 | 1.364 | 2.269 | 3.240 | 5.033 | 0.709 | 2.935 | 1.269 |
| Hydromorphone 6 mg | 39.047 | 4.214 | 2.787 | 2.933 | 4.491 | 2.497 | 0.872 | 0.533 | 0.329 | 0.305 | 0.491 | 1.118 | 0.524 |
| Placebo | 3.274 | 1.200 | 1.775 | 1.193 | 0.514 | 0.933 | 0.673 | 0.625 | 1.297 | 0.522 | 0.654 | 0.993 | 0.285 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme sedation 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 30.979 | 5.401 | 7.048 | 4.897 | 5.774 | 2.445 | 3.354 | 3.894 | 3.395 | 4.996 | 1.032 | 3.299 | 0.086 |
| Hydromorphone 6 mg | 14.504 | 3.979 | 3.508 | 1.975 | 3.462 | 2.873 | 0.923 | 2.233 | 1.142 | 1.041 | 0.567 | 1.403 | 2.408 |
| Placebo | 3.399 | 1.199 | 3.126 | 1.135 | 0.661 | 1.110 | 1.152 | 2.348 | 1.787 | 0.506 | 1.155 | 0.858 | 0.344 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme bad effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 11.046 | 1.107 | 1.507 | 1.228 | 1.117 | 0.690 | 0.525 | 0.642 | 0.508 | 0.434 | 0.403 | 0.569 | 0.368 |
| Hydromorphone 6 mg | 7.145 | 1.159 | 1.120 | 0.926 | 0.663 | 0.817 | 0.521 | 0.666 | 0.553 | 0.395 | 0.420 | 0.629 | 0.387 |
| Placebo | 4.797 | 1.117 | 0.980 | 0.842 | 0.691 | 0.785 | 0.494 | 0.760 | 0.544 | 0.376 | 0.504 | 0.523 | 0.393 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme good effect 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 61.640 | 7.072 | 5.263 | 7.395 | 8.130 | 2.270 | 1.164 | 2.225 | 3.146 | 4.815 | 0.681 | 3.712 | 2.251 |
| Hydromorphone 6 mg | 43.888 | 4.252 | 2.364 | 2.930 | 4.508 | 2.264 | 0.761 | 0.504 | 0.188 | 0.270 | 0.564 | 1.023 | 0.681 |
| Placebo | 3.131 | 1.239 | 1.768 | 1.221 | 0.476 | 0.863 | 0.410 | 0.574 | 1.289 | 0.399 | 0.536 | 1.149 | 0.550 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme high from the drug 30 minutes (± 5 minutes) before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes (± 5 minutes) after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 53.597 | 6.240 | 5.173 | 5.731 | 7.737 | 2.304 | 2.555 | 2.481 | 3.277 | 4.534 | 0.624 | 2.460 | 0.994 |
| Hydromorphone 6 mg | 33.052 | 4.444 | 2.539 | 3.028 | 4.251 | 2.406 | 0.878 | 0.540 | 0.261 | 0.265 | 0.417 | 0.987 | 0.458 |
| Placebo | 2.654 | 1.386 | 2.020 | 1.362 | 0.595 | 0.860 | 0.463 | 0.661 | 1.431 | 0.519 | 0.644 | 0.950 | 0.289 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Participants completed a visual analog scale (VAS) that ranged from 0 - 100, with 0 meaning not at all, and 100 meaning the most extreme liking of the drug 30 minutes before and 15, 30 , 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 minutes after hydromorphone challenge. The drug in question was hydromorphone (6 or 18 mg) or placebo.~For each hydromorphone challenge week, a mixed-effects model with period (where period is day), hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect were used for analysis.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 63.503 | 8.374 | 4.750 | 6.246 | 7.211 | 2.258 | 3.600 | 2.550 | 3.203 | 4.616 | 0.722 | 4.709 | 3.756 |
| Hydromorphone 6 mg | 48.252 | 5.103 | 2.436 | 2.183 | 3.849 | 1.785 | 0.789 | 0.521 | 0.225 | 0.328 | 0.507 | 1.154 | 0.939 |
| Placebo | 2.892 | 1.447 | 1.850 | 1.320 | 0.534 | 1.048 | 0.440 | 0.672 | 1.270 | 0.451 | 0.596 | 1.471 | 0.973 |
"This endpoint explores the correlation between the reinforcing effects of hydromorphone and simulated mu opioid receptor occupancy.~Data are reported as change from placebo least square mean of Log10 transformed values for reinforcing effects. Reinforcing Effects tasks began >= 5 hours after hydromorphone challenge. Participants made 12 choices between a preference for working for the amount of hydromorphone dosed that day or for money. The hydromorphone break point value is assigned to the highest level of hydromorphone units earned, with 1 unit having a breakpoint value of 5 and 12 units with a value of 2160.~Change from placebo was calculated as Active Challenge result - Placebo Challenge result. Values that approach 0 (implying little difference between the Active Challenge result and the Placebo Challenge result) indicate effectiveness of the opioid blockade.~Row titles include Study Week: predicted mu opioid receptor occupancy for 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | log10 transformed ratio (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00 % | Week 1: 67.88/67.09 % | Week 2: 66.06/66.49 % | Week 3: 66.00/66.44 % | Week 4: 65.11/65.35 % | Week 5: 76.29/76.42 % | Week 6: 75.70/75.69 % | Week 7: 75.64/75.43 % | Week 8: 74.79/75.18 % | Week 9: 73.97/74.04 % | Week 10: 73.08/74.18 % | Week 11: 73.05/73.51 % | Week 12: 71.31/71.30 % | |
| Hydromorphone 18 mg | 0.89 | 0.41 | 0.63 | 0.40 | 0.82 | 0.16 | 0.43 | 0.38 | 0.37 | 0.48 | 0.20 | 0.32 | 0.69 |
| Hydromorphone 6 mg | 0.93 | 0.27 | 0.32 | 0.41 | 0.60 | -0.04 | 0.05 | 0.31 | 0.23 | 0.04 | 0.01 | -0.09 | 0.26 |
"TEAE=any untoward medical occurrence that develops or worsens in severity after administration of study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required intervention to prevent one of the outcomes listed above.~All adverse events that occurred between Day 1 to Day 91 are reported under the Depot Buprenorphine treatment arm.~Adverse events that occurred on the day of a hydromorphone challenge are also reported under the appropriate hydromorphone challenge arm." (NCT02044094)
Timeframe: Depot Buprenorphine: Day 1 to Day 91. The three hydromorphone challenge levels were randomly assigned to one day in each of the three-day groupings spanning 12 weeks: Days 5-7, 11-14, 19-21, 26-28, 33-35, 40-42, 47-49, 54-56, 61-63, 68-70, 75-77, 82-84
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| >=1 TEAE | >=1 Severe TEAE | Deaths | >=1 SAE other than death | Withdrew from study due to a TEAE | |
| Hydromorphone 18 mg Challenge | 25 | 0 | 0 | 0 | 0 |
| Hydromorphone 6 mg Challenge | 26 | 0 | 0 | 0 | 0 |
| Placebo Challenge | 29 | 0 | 0 | 0 | 0 |
"TEAE=any untoward medical occurrence that develops or worsens in severity after administration of study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required intervention to prevent one of the outcomes listed above.~All adverse events that occurred between Day 1 to Day 91 are reported under the Depot Buprenorphine treatment arm.~Adverse events that occurred on the day of a hydromorphone challenge are also reported under the appropriate hydromorphone challenge arm." (NCT02044094)
Timeframe: Depot Buprenorphine: Day 1 to Day 91. The three hydromorphone challenge levels were randomly assigned to one day in each of the three-day groupings spanning 12 weeks: Days 5-7, 11-14, 19-21, 26-28, 33-35, 40-42, 47-49, 54-56, 61-63, 68-70, 75-77, 82-84
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| >=1 TEAE | >=1 TEAE related to study drug | >=1 Severe TEAE | Deaths | >=1 SAE other than death | Withdrew from study due to a TEAE | |
| Depot Buprenorphine | 39 | 25 | 0 | 0 | 0 | 0 |
"PK Sampling Schedule:~Day -17 to -15: before hydromorphone admin~Day -4: before Suboxone admin~Day 2: 24 hours after RBP-6000 admin~Days 5-7, 12-14, 19-21 and 26-28: immediately before hydromorphone admin~Days 29: before RBP-6000 admin~Day 30: 24 hours after RBP-6000 admin~Days 33-35, 40-42, 47-49, 54-56, 61-63, 68-70, 75-77, and 82-84: immediately before hydromorphone admin" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | ng/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 0.000 | 2.042 | 1.970 | 1.916 | 1.812 | 3.667 | 3.521 | 3.466 | 3.497 | 3.210 | 1.150 | 1.083 | 2.624 |
| Hydromorphone 6 mg | 0.000 | 2.164 | 1.874 | 1.882 | 1.776 | 3.649 | 3.530 | 3.495 | 3.365 | 3.122 | 3.039 | 2.985 | 2.646 |
| Placebo | 0.000 | 2.030 | 1.892 | 1.933 | 1.722 | 3.684 | 3.423 | 3.427 | 3.326 | 3.156 | 2.985 | 3.117 | 2.626 |
"A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to model the relationship between buprenorphine plasma concentrations and brain μORO based on 2 published clinical trials. This model used individual buprenorphine plasma concentrations measured to derive muORO individual predictions that were further described using summary statistics. The relationship between buprenorphine plasma concentration and μORO was best described by a maximal effect (Emax) model:~µORO = E(max)*Cp / EC(50) + Cp~Where Cp is the plasma concentration of buprenorphine, Emax is the maximal μORO, and EC50 is the plasma concentration of buprenorphine that is expected to achieve 50% of the maximal μORO. A direct (instantaneous) relationship between buprenorphine plasma concentration and µORO, i.e. without equilibration delay, was assumed.~Row title format: Study Week: buprenorphine plasma concentrations for placebo/ 6 mg / 18 mg challenge dosages" (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | percentage receptor occupancy (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1: 0.00/0.00/0.00 | Week 1: 2.03/2.16/2.04 | Week 2: 1.89/1.87/1.97 | Week 3: 1.93/1.88/1.92 | Week 4: 1.72/1.78/1.81 | Week 5: 3.68/3.65/3.67 | Week 6: 3.42/3.53/3.52 | Week 7: 3.43/3.50/3.47 | Week 8: 3.33/3.37/3.50 | Week 9: 3.16/3.12/3.21 | Week 10: 2.99/3.04/3.19 | Week 11: 3.12/2.99/3.08 | Week 12: 2.63/2.65/2.62 | |
| Hydromorphone 18 mg | 0.000 | 67.089 | 66.485 | 66.438 | 65.349 | 76.417 | 75.686 | 75.429 | 75.179 | 74.036 | 74.179 | 73.507 | 71.303 |
| Hydromorphone 6 mg | 0.000 | 67.875 | 66.059 | 66.000 | 65.108 | 76.285 | 75.699 | 75.641 | 74.792 | 73.970 | 73.075 | 73.054 | 71.313 |
| Placebo | 0.000 | 67.077 | 66.071 | 66.442 | 64.270 | 76.346 | 75.432 | 75.351 | 74.544 | 74.000 | 73.002 | 73.385 | 71.274 |
"This outcome reports observed values used in the Change from Placebo....' endpoint that follows.~Reinforcing Effects tasks began >= 5 hours after hydromorphone challenge. Participants made 12 choices between a preference for working for the amount of hydromorphone dosed that day or for money. The hydromorphone break point value is assigned to the highest level of hydromorphone units earned, with 1 unit having a breakpoint value of 5 and 12 units with a value of 2160.~A repeated measures mixed-effects analysis of variance (ANOVA) was performed with the log transformed hydromorphone break point value as the dependent variable with period, hydromorphone sequence and hydromorphone dose as fixed effects, and subject nested within hydromorphone sequence as a random effect.~Blockade is achieved if the upper bound of the 95% confidence interval is <= to the non-inferiority margin of 11." (NCT02044094)
Timeframe: Baseline (Week -1), Weeks 1-12 (RBP-6000 admin on Weeks 1 and 5)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Week -1 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 7.042 | 5.708 | 5.496 | 5.669 | 6.030 | 4.936 | 5.282 | 5.965 | 4.747 | 5.437 | 4.997 | 5.076 | 5.615 |
| Hydromorphone 6 mg | 7.121 | 5.379 | 4.779 | 5.706 | 5.533 | 4.470 | 4.419 | 5.808 | 4.418 | 4.432 | 4.578 | 4.114 | 4.623 |
| Placebo | 4.984 | 4.767 | 4.036 | 4.760 | 4.144 | 4.564 | 4.303 | 5.092 | 3.899 | 4.342 | 4.546 | 4.330 | 4.029 |
"The ability of RBP-6000 to reduce the reinforcing effects of hydromorphone used money as a choice alternative to hydromorphone.~Reinforcing Effects Tasks began no earlier than 5 hours after randomised hydromorphone administration for each day. Each test consisted of the participant making 12 choices between a preference for working for the amount of hydromorphone dosed earlier that day or for money (each choice therefore has a scale of 0-12). The hydromorphone break point value is the ratio of the highest number of choices for hydromorphone to the highest number of choices for money. Hydromorphone breakpoint values were then analysed by week using a repeated measures mixed-effects model with period, hydromorphone sequence, and hydromorphone dose as fixed effects and subject nested within hydromorphone sequence as a random effect. Analyses were carried out on the log10 transformed hydromorphone breakpoint value." (NCT02044094)
Timeframe: Weeks 1 (Days 5-7), 2 (Days 12-14), 3 (Days 19-21), 4 (Days 26-28), 5 (Days 33-35), 6 (Days 40-42), 7 (Days 47-49), 8 (Days 53-56), 9 (Days 61-63), 10 (Days 68-70), 11 (Days 75-77), 12 (Days 82-84)
| Intervention | log10 transformed ratio (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Hydromorphone 18 mg | 2.479 | 2.387 | 2.462 | 2.619 | 2.144 | 2.294 | 2.591 | 2.062 | 2.361 | 2.170 | 2.205 | 2.438 |
| Hydromorphone 6 mg | 2.336 | 2.075 | 2.478 | 2.403 | 1.941 | 1.919 | 2.522 | 1.919 | 1.925 | 1.988 | 1.787 | 2.008 |
| Placebo | 2.070 | 1.753 | 2.067 | 1.800 | 1.982 | 1.869 | 2.212 | 1.694 | 1.886 | 1.974 | 1.880 | 1.750 |
(NCT00737737)
Timeframe: 4 weeks
| Intervention | ng/ml (Number) |
|---|---|
| Opioid | NA |
| Placebo | NA |
(NCT00737737)
Timeframe: 4 weeks
| Intervention | ng/ml (Number) |
|---|---|
| Opioid | NA |
| Placebo | NA |
47 reviews available for fentanyl and Addiction, Opioid
| Article | Year |
|---|---|
A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y
Topics: Animals; Fentanyl; Glucagon-Like Peptide-1 Receptor; Opioid-Related Disorders; Rats; Receptors, Neur | 2021 |
Harm Reduction in Health Care Settings.
Topics: Alcohol Drinking; Analgesics, Opioid; Behavior, Addictive; Central Nervous System Stimulants; Counse | 2022 |
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Disease Management; Drug Overdose; Female; Fe | 2022 |
The North American opioid epidemic: opportunities and challenges for clinical laboratories.
Topics: Analgesics, Opioid; Fentanyl; Humans; Laboratories, Clinical; Opioid Epidemic; Opioid-Related Disord | 2022 |
Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse.
Topics: Analgesics, Opioid; Brain; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Vaccines | 2022 |
A Neuropharmacological Model to Explain Buprenorphine Induction Challenges.
Topics: Algorithms; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Opioid-Related Disorders | 2022 |
Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Cues; Fentanyl; Glucagon-Like Peptide-1 Receptor; Heroin | 2022 |
Pharmacotherapy of Opioid Use Disorder-Update and Current Challenges.
Topics: Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Opiate Substitution Treatment; Opioid-Related D | 2022 |
Unintentional overdoses: understanding the fentanyl landscape and reducing harm.
Topics: Adolescent; Analgesics, Opioid; Child; Drug Overdose; Fentanyl; Harm Reduction; Humans; Naloxone; Op | 2023 |
All Hands on Deck: We Need Multiple Approaches To Uncover the Neuroscience behind the Opioid Overdose Crisis.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Unit | 2023 |
Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders | 2023 |
Non-fentanyl new synthetic opioids - An update.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Naloxone; Opioid-Related Disorde | 2023 |
Focus on fentanyl in females: Sex and gender differences in the physiological and behavioral effects of fentanyl.
Topics: Analgesics, Opioid; Animals; Drug Overdose; Female; Fentanyl; Humans; Male; Opioid-Related Disorders | 2023 |
The Role of Non-Pharmaceutical Fentanyl-Contaminated Counterfeit Oxycodone in Increasing Opioid Overdoses: A Commentary Review.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Oxyc | 2023 |
Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Germany; Humans | 2019 |
The Deadly Trio: Heroin, FentaNYL, and Carfentanil.
Topics: Drug Overdose; Fentanyl; Heroin; Humans; Nursing Diagnosis; Opioid-Related Disorders; United States | 2020 |
A Brief Overview of Identification and Management of Opiate Use Disorder in the Primary Care Setting.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Primary Health Care | 2019 |
The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Illicit Drugs; Opioid-Related Disorders | 2019 |
The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid Crisis.
Topics: Analgesics, Opioid; Drug Contamination; Drug Overdose; Fentanyl; Global Health; Humans; Illicit Drug | 2020 |
Reasons to avoid fentanyl.
Topics: Analgesics, Opioid; Fentanyl; Humans; Narcotics; Opioid-Related Disorders; Pain; Public Health; Unit | 2020 |
Illicit synthetic opioid consumption in Asia and the Pacific: Assessing the risks of a potential outbreak.
Topics: Asia; Australia; China; Drug Overdose; Fentanyl; Heroin; Humans; India; Myanmar; Opioid-Related Diso | 2021 |
Carfentanil - from an animal anesthetic to a deadly illicit drug.
Topics: Analgesics, Opioid; Chromatography, Liquid; Drug Contamination; Drug Overdose; Fentanyl; Forensic To | 2021 |
The opioid crisis and HIV in the USA: deadly synergies.
Topics: Adolescent; Adult; Analgesics, Opioid; Black or African American; Case-Control Studies; Disease Outb | 2021 |
Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Disorders; Prescription | 2018 |
Three Cases of Fatal Acrylfentanyl Toxicity in the United States and a Review of Literature.
Topics: Adult; Analgesics, Opioid; Autopsy; Cause of Death; Chromatography, Liquid; Drug Overdose; Fatal Out | 2018 |
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review.
Topics: Analgesics, Opioid; Animals; Chromatography, Liquid; Designer Drugs; Fentanyl; Humans; Naloxone; Nar | 2018 |
Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin.
Topics: Analgesics, Opioid; Epidemics; Fentanyl; Heroin; Humans; Illicit Drugs; Opioid-Related Disorders; Ps | 2018 |
DARK Classics in Chemical Neuroscience: Fentanyl.
Topics: Analgesics, Opioid; Anesthesia, General; Drug Industry; Drug Overdose; Epidemics; Fentanyl; Humans; | 2018 |
Abuse of fentanyl: An emerging problem to face.
Topics: Analgesics, Opioid; Dosage Forms; Drug Contamination; Drug Overdose; Drug Trafficking; Fentanyl; Hum | 2018 |
The opioid crisis in Canada: a national perspective.
Topics: Age Factors; Canada; Drug Overdose; Emergency Medical Services; Fentanyl; Hospitalization; Humans; I | 2018 |
Is Australia ready for fentanyl?
Topics: Analgesics, Opioid; Australia; Drug Trafficking; Fentanyl; Humans; Opioid-Related Disorders | 2018 |
Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
Topics: Adrenergic beta-1 Receptor Antagonists; Analgesics, Opioid; Anesthesia; Fentanyl; Humans; Opioid-Rel | 2018 |
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.
Topics: Analgesics, Opioid; Fentanyl; Humans; Opiate Substitution Treatment; Opioid-Related Disorders; Recep | 2019 |
Carfentanil: a narrative review of its pharmacology and public health concerns.
Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Illicit Drugs; Naloxone; Narcotic Antagonists; Opioid | 2019 |
The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.
Topics: Analgesics, Opioid; Animals; Drug Overdose; Fentanyl; Harm Reduction; Humans; Illicit Drugs; Naloxon | 2019 |
Development of vaccines to treat opioid use disorders and reduce incidence of overdose.
Topics: Antigen-Antibody Complex; Blood-Brain Barrier; Drug Overdose; Fentanyl; Heroin; Humans; Opiate Subst | 2019 |
[Death from fentanyl: Causative and preventive approaches in Bavaria].
Topics: Analgesics, Opioid; Cause of Death; Chronic Pain; Drug Overdose; Drug Substitution; Fentanyl; German | 2016 |
Alghedon Fentanyl Transdermal System.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Fentanyl; | 2017 |
A review: Fentanyl and non-pharmaceutical fentanyls.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Disorders; United States | 2017 |
Transdermal fentanyl: pharmacology and toxicology.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Carriers; Drug Overdose; Fentan | 2009 |
Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Topics: Administration, Buccal; Algorithms; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; D | 2010 |
[Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency].
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Chronic Pain; Diabetic Neuropathies; Dose-Response Relati | 2013 |
Postoperative care of the chronic opioid-consuming patient.
Topics: Analgesia; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Tolerance; Fentanyl; Humans; Opio | 2005 |
Major increases in opioid analgesic abuse in the United States: concerns and strategies.
Topics: Analgesics, Opioid; Fentanyl; Humans; Hydrocodone; Morphine; Opioid-Related Disorders; Oxycodone; Un | 2006 |
Fentanyl and its analogues in clinical and forensic toxicology.
Topics: Analgesics, Opioid; Diagnosis, Differential; Fentanyl; Forensic Medicine; Gas Chromatography-Mass Sp | 2005 |
Pain management in the critically ill child.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Child, Preschool; Critical Illness; Fentan | 2001 |
Pediatric uses of opioids.
Topics: Child; Child, Preschool; Codeine; Drug Interactions; Fentanyl; Humans; Infant; Infant, Newborn; Mepe | 1989 |
7 trials available for fentanyl and Addiction, Opioid
365 other studies available for fentanyl and Addiction, Opioid
| Article | Year |
|---|---|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Topics: Animals; Aorta, Thoracic; Cocaine; Cyclic AMP; Electric Stimulation; Guinea Pigs; Humans; Ileum; In | 1998 |
The fourth wave of the US opioid epidemic and its implications for the rural US: A federal perspective.
Topics: Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Male; Opioid Epidemic; Opioid-Related Disorders | 2021 |
Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.
Topics: Adolescent; Adult; Buprenorphine; Cross-Sectional Studies; Databases, Factual; Female; Fentanyl; Hum | 2021 |
Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Cohort Studies; | 2021 |
When Fentanyl Finds an Outlier: Talking With Teenagers About the Danger.
Topics: Adolescent; Fentanyl; Health Education; Humans; Male; Opioid-Related Disorders; Psychology, Adolesce | 2021 |
Lay knowledge and practices of methamphetamine use to manage opioid-related overdose risks.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Humans; Methamphetamine; Opiate Overdose | 2022 |
Addressing fentanyl use disorder with fentanyl-assisted treatment.
Topics: Analgesics, Opioid; Fentanyl; Global Health; Humans; Illicit Drugs; Opioid-Related Disorders | 2022 |
Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fentanyl; Humans; Nalox | 2022 |
Optimization of the medication-use process for fentanyl patches at a small community hospital.
Topics: Analgesics, Opioid; Fentanyl; Hospitals, Community; Humans; Opioid-Related Disorders; Pharmacists | 2022 |
Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019.
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Disor | 2021 |
Thirteen Cases of Valeryl Fentanyl in Michigan: A Call for Expanding Opioid Testing.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Michigan; Opioid-Related Disorders; United Stat | 2021 |
Notes from the Field: Testing for Nonprescribed Fentanyl and Percentage of Positive Test Results Among Patients with Opioid Use Disorder - United States, 2019-2020.
Topics: COVID-19; Drug Prescriptions; Fentanyl; Humans; Opioid-Related Disorders; Substance Abuse Detection; | 2021 |
Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality.
Topics: Adult; Aftercare; Analgesics, Opioid; Drug Overdose; Fentanyl; Hospitalization; Humans; Opioid-Relat | 2022 |
The Public Health Approach to the Worsening Opioid Crisis in the United States Calls for Harm Reduction Strategies to Mitigate the Harm From Opioid Addiction and Overdose Deaths.
Topics: Analgesics, Opioid; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Harm R | 2022 |
Association between fentanyl treatment for acute pain in the emergency department and opioid use two weeks after discharge.
Topics: Acute Pain; Adult; Aged; Analgesics, Opioid; Case-Control Studies; Emergency Service, Hospital; Fema | 2022 |
Opioid Use Disorder Treatment in the Age of Fentanyl.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Patients | 2022 |
"It's probably going to save my life;" attitudes towards treatment among people incarcerated in the era of fentanyl.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Health Knowledge, Attitudes, Practice; Humans; Opioid-R | 2022 |
Stress reveals a specific behavioral phenotype for opioid abuse susceptibility.
Topics: Analgesics, Opioid; Animals; Fentanyl; Mice; Opioid-Related Disorders; Phenotype; Stress, Psychologi | 2022 |
Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia.
Topics: Adult; Analgesics, Opioid; Australia; Drug Overdose; Female; Fentanyl; Heroin; Humans; Male; Opioid- | 2022 |
Fentanyl-induced changes in brain activity in awake nonhuman primates at 9.4 Tesla.
Topics: Animals; Brain; Fentanyl; Magnetic Resonance Imaging; Neural Pathways; Opioid-Related Disorders; Pri | 2022 |
Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Mathematical Concepts; Models, Biologic | 2022 |
Fentanyl Contamination as a Risk Priority: the Impact of the Fentanyl Epidemic on Club Drug-Using Behaviours.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disorders | 2022 |
Opioid withdrawal management in the fentanyl era.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders | 2022 |
New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Humans; Male; Middle A | 2022 |
Case report: acute care management of severe opioid withdrawal with IV fentanyl.
Topics: Analgesics, Opioid; Fentanyl; Humans; Narcotics; Opioid-Related Disorders; Research Report | 2022 |
Impact of the naloxone standing order on trends in opioid fatal overdose: an ecological analysis.
Topics: Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Humans; Naloxone; Narcotic Antagonists; Opiate | 2022 |
Buprenorphine Treatment of Fentanyl-Related Opioid Use Disorder.
Topics: Buprenorphine; Fentanyl; Humans; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Fentanyl overdose concerns among people who inject drugs: The role of sex, racial minority status, and overdose prevention efforts.
Topics: Analgesics, Opioid; Drug Overdose; Drug Users; Ethnic and Racial Minorities; Female; Fentanyl; Heroi | 2023 |
The United Kingdom's first unsanctioned overdose prevention site; A proof-of-concept evaluation.
Topics: Analgesics, Opioid; Cocaine; Drug Overdose; Fentanyl; Humans; Male; Opioid-Related Disorders | 2022 |
Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making.
Topics: Adult; Analgesics, Opioid; COVID-19; Drug Overdose; Female; Fentanyl; Humans; Male; Opiate Overdose; | 2022 |
Signals of increasing co-use of stimulants and opioids from online drug forum data.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Drug Overdose; Fentanyl; Humans; Methamphetam | 2022 |
Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.
Topics: Analgesics, Opioid; Drug Overdose; Drug Users; Fentanyl; Humans; Naloxone; New York City; Opiate Ove | 2022 |
Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Naloxone; Narcotic Antagonists; Nasal Sprays; O | 2022 |
Characteristics of Adults Aged ≥18 Years Evaluated for Substance Use and Treatment Planning - United States, 2019.
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Pr | 2022 |
Development of an intravenous low-dose buprenorphine initiation protocol.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Methadone; Opiate Substitution Trea | 2022 |
"It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opiate Overdose; Opioid-Related | 2022 |
The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Disorders; Policy; Pract | 2022 |
How much illegally manufactured fentanyl could the U.S. be consuming?
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Disorders; United States | 2022 |
Adapting methadone inductions to the fentanyl era.
Topics: Analgesics, Opioid; Fentanyl; Heroin; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Evidence of Pre-mortem Opioid Use among Fentanyl Overdose Decedents in a Safety Net Healthcare System.
Topics: Analgesics, Opioid; Delivery of Health Care; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorde | 2022 |
Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Fentanyl; Male; Methadone; Narcotics; Opioid-Related Dis | 2022 |
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders | 2022 |
A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action | 2022 |
Determining the feasibility for an overdose prevention line to support substance users who use alone.
Topics: Analgesics, Opioid; Drug Overdose; Feasibility Studies; Fentanyl; Humans; Needle-Exchange Programs; | 2022 |
Years of Life Lost to Unintentional Drug Overdose Rapidly Rising in the Adolescent Population, 2016-2020.
Topics: Adolescent; Analgesics, Opioid; Commerce; Drug Overdose; Female; Fentanyl; Humans; Male; Opioid-Rela | 2023 |
Characteristics and correlates of fentanyl preferences among people with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Fentanyl; Heroin; Humans; Opioid-Related Di | 2022 |
Impact of high-access exercise prior to and during early adolescence on later vulnerability to opioid use and relapse in male rats.
Topics: Analgesics, Opioid; Animals; Brain-Derived Neurotrophic Factor; Cues; Fentanyl; Male; Opioid-Related | 2022 |
'It's the same thing as giving them CPR training': rural first responders' perspectives on naloxone.
Topics: Analgesics, Opioid; Cardiopulmonary Resuscitation; Drug Overdose; Emergency Responders; Fentanyl; Hu | 2022 |
Sensitivity of a fentanyl-vs.-social interaction choice procedure to environmental and pharmacological manipulations.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Male; Naltr | 2022 |
Combating illicit fentanyl: Will increased Chinese regulation generate a public health crisis in India?
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disorders; Public | 2022 |
The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database.
Topics: Analgesics, Opioid; Bayes Theorem; Codeine; Fentanyl; Humans; Morphine; Opioid Epidemic; Opioid-Rela | 2023 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria.
Topics: Cyclonic Storms; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Risk-Ta | 2022 |
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
Topics: Analgesics, Opioid; Animals; Body Mass Index; Cattle; Female; Fentanyl; Morphine; Narcotic Antagonis | 2023 |
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
Topics: Analgesics, Opioid; Animals; Body Mass Index; Cattle; Female; Fentanyl; Morphine; Narcotic Antagonis | 2023 |
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
Topics: Analgesics, Opioid; Animals; Body Mass Index; Cattle; Female; Fentanyl; Morphine; Narcotic Antagonis | 2023 |
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
Topics: Analgesics, Opioid; Animals; Body Mass Index; Cattle; Female; Fentanyl; Morphine; Narcotic Antagonis | 2023 |
Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disor | 2022 |
Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disor | 2022 |
Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disor | 2022 |
Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disor | 2022 |
Oral oxycodone self-administration leads to features of opioid misuse in male and female mice.
Topics: Analgesics, Opioid; Animals; Female; Fentanyl; Male; Mice; Opioid-Related Disorders; Oxycodone; Rein | 2023 |
Antibiotic Knockdown of Gut Bacteria Sex-Dependently Enhances Intravenous Fentanyl Self-Administration in Adult Sprague Dawley Rats.
Topics: Analgesics, Opioid; Animals; Fentanyl; Male; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; R | 2022 |
Opioid-related deaths in Ontario correctional facilities and penitentiaries (2009-2019).
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Humans; Male; Middle Aged; O | 2023 |
Strategies to Reduce Harm: An Expert Panel Discussion on the Fentanyl Crisis.
Topics: Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders | 2023 |
Using Evidence to Inform Legislation Aimed at Curbing Fentanyl Deaths.
Topics: Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders | 2023 |
Rural communities face more than an opioid crisis: Reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Infant, Newborn; Methamphetamine; Neonatal Abst | 2023 |
Characterization of Unintentional Deaths Among Buprenorphine Users.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Drug Overdose; Fentanyl; Humans; Methamphetamine | 2023 |
Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
Topics: Analgesics, Opioid; Buprenorphine; Fentanyl; Heroin; Humans; Opioid-Related Disorders | 2023 |
Estradiol Enhances the Development of Addiction-Like Features in a Female Rat Model of Opioid Use Disorder.
Topics: Animals; Estradiol; Ethanol; Female; Fentanyl; Humans; Male; Motivation; Opioid-Related Disorders; R | 2023 |
Medical Opioid Disposal in Fukuoka and Kumamoto Cities.
Topics: Analgesics, Opioid; Cities; Fentanyl; Humans; Opioid-Related Disorders; Oxycodone | 2023 |
Stimulant use among patients in opioid treatment settings: Provider perspectives.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Methadone; Opiate Substitution Treatment; Opioi | 2023 |
Trends and correlated outcomes in population-level prescription opioid and transdermal fentanyl use in Israel.
Topics: Analgesics, Opioid; Fentanyl; Humans; Israel; Longitudinal Studies; Opioid-Related Disorders; Prescr | 2023 |
Chronic inflammatory pain promotes place preference for fentanyl in male rats but does not change fentanyl self-administration in male and female rats.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Female; Fentanyl; Male; Motivation; Opioid-Related Disord | 2023 |
IGF-1 Microinjection in the Prefrontal Cortex Attenuates Fentanyl-Seeking Behavior in Mice.
Topics: Animals; Drug-Seeking Behavior; Fentanyl; Insulin-Like Growth Factor I; Mice; Microinjections; Opioi | 2023 |
Legal Limitations Associated with Microdosing Buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Opioid-Related Disorders | 2023 |
Guidance for Handling the Increasing Prevalence of Drugs Adulterated or Laced With Fentanyl.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Phar | 2023 |
National Trends in Pediatric Deaths From Fentanyl, 1999-2021.
Topics: Analgesics, Opioid; Child; Drug Overdose; Female; Fentanyl; Humans; Opioid-Related Disorders; Perina | 2023 |
Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.
Topics: Analgesics, Opioid; Chromatography, Liquid; Cocaine; Fentanyl; Heroin; Humans; Methadone; Methamphet | 2023 |
Burden of opioid toxicity death in the fentanyl-dominant era for people who experience incarceration in Ontario, Canada, 2015-2020: a whole population retrospective cohort study.
Topics: Adult; Analgesics, Opioid; Correctional Facilities; Female; Fentanyl; Humans; Male; Ontario; Opioid- | 2023 |
Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Crack Cocaine; Drug Overdose; Fentanyl; Heroin; | 2023 |
Accelerated Fentanyl Metabolism During Pregnancy and Impact on Prenatal Drug Testing.
Topics: Analgesics, Opioid; Child; Female; Fentanyl; Humans; Opioid-Related Disorders; Pregnancy; Retrospect | 2023 |
Association of Intraoperative Opioid Administration With Postoperative Pain and Opioid Use.
Topics: Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Hydromorphone; Male; Middle Aged; Opioid-Relate | 2023 |
Correlation Between Opioid Drug Prescription and Opioid-Related Mortality in Spain as a Surveillance Tool: Ecological Study.
Topics: Analgesics, Opioid; Drug Prescriptions; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; | 2023 |
Claustral neurons projecting to frontal cortex restrict opioid consumption.
Topics: Analgesics, Opioid; Animals; Basal Ganglia; Claustrum; Fentanyl; Frontal Lobe; Humans; Mice; Neurons | 2023 |
[Opioid dependent patient with two prescribers].
Topics: Analgesics, Opioid; Fentanyl; General Practitioners; Humans; Opioid-Related Disorders; Oxycodone; Pr | 2023 |
Opioid use disorder: is history repeating itself with sufentanil?
Topics: Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders; Sufentanil | 2023 |
Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.
Topics: Buprenorphine; Cohort Studies; Female; Fentanyl; Humans; Male; Opioid-Related Disorders; Retrospecti | 2023 |
Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opiate Overdose; Opioid-Related Disorders; Unit | 2023 |
Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge.
Topics: Adjuvants, Immunologic; Analgesics, Opioid; Animals; Antigens; Fentanyl; Haptens; Mice; Opioid-Relat | 2023 |
Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
Topics: Analgesics, Opioid; Cocaine; Drug Overdose; Emergency Service, Hospital; Fentanyl; Humans; Illicit D | 2023 |
Shift in hospital opioid use during the COVID-19 pandemic in Brazil: a time-series analysis of one million prescriptions.
Topics: Adult; Analgesics, Opioid; Brazil; COVID-19; Fentanyl; Humans; Methadone; Morphine; Opioid-Related D | 2023 |
Trends in Self-Reported Fentanyl and Other Illicit Substance Use in South Carolina Emergency Department Patients, 2020-2022.
Topics: Analgesics, Opioid; Cocaine; Drug Overdose; Emergency Service, Hospital; Fentanyl; Heroin; Humans; O | 2023 |
Postmortem toxicology findings from the Camden Opioid Research Initiative.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Naloxone; Opioid-Related Disorders; Pandemics; | 2023 |
Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System.
Topics: Administration, Cutaneous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics, Opio | 2020 |
A case report on potential postmortem redistribution of furanyl fentanyl and 4-ANPP.
Topics: Analgesics, Opioid; Bile; Chromatography, Liquid; Fentanyl; Forensic Toxicology; Furans; Gastrointes | 2019 |
Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?
Topics: Analgesics, Opioid; Benzodiazepines; Cannabinoids; Computer Simulation; Cost-Benefit Analysis; Desig | 2019 |
Increases in Online Posts About Synthetic Opioids Preceding Increases in Synthetic Opioid Death Rates: a Retrospective Observational Study.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Retrospective Studies | 2019 |
Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Drug Dosage Calculations; Drug Overdose; Emergency Serv | 2020 |
Prevalence of fentanyl exposure and knowledge regarding the risk of its use among emergency department patients with active opioid use history at an urban medical center in Baltimore, Maryland.
Topics: Analgesics, Opioid; Baltimore; Cross-Sectional Studies; Emergency Service, Hospital; Female; Fentany | 2020 |
Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains.
Topics: Analgesics, Opioid; Animals; Anxiety; Choice Behavior; Conditioning, Operant; Female; Fentanyl; Geno | 2020 |
Recent fentanyl use among people who inject drugs: Results from a rapid assessment in Baltimore, Maryland.
Topics: Age Factors; Analgesics, Opioid; Baltimore; Cohort Studies; Female; Fentanyl; Health Knowledge, Atti | 2019 |
Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Fentanyl; Heroin; Humans; Male; Met | 2019 |
Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities.
Topics: Adolescent; Adult; Baltimore; Boston; Cross-Sectional Studies; Drug Overdose; Drug Users; Female; Fe | 2019 |
Designing traceable opioid material
Topics: Analgesics, Opioid; Calibration; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Predicti | 2019 |
"Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Fentanyl; Heroin Dependence; | 2019 |
Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder.
Topics: Adult; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Heroin; Hospitalization; Humans; Lo | 2019 |
Post-mortem analysis of prescription opioids-A follow-up examination by LC-MS/MS with focus on fentanyl.
Topics: Adult; Aged, 80 and over; Analgesics, Opioid; Chromatography, Liquid; Drug Prescriptions; Female; Fe | 2019 |
A deadly trend in fentanyl fatalities (England, 1998-2017).
Topics: Analgesics, Opioid; Drug Overdose; England; Fentanyl; Humans; Male; Opioid-Related Disorders | 2020 |
Higher naloxone dosing may be required for opioid overdose.
Topics: Adult; Analgesics, Opioid; Cardiopulmonary Resuscitation; Cyanosis; Drug Overdose; Female; Fentanyl; | 2019 |
Examining opioid-involved overdose mortality trends prior to fentanyl: New York City, 2000-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Sectional Studies; Death Certi | 2019 |
Association of Law Enforcement Seizures of Heroin, Fentanyl, and Carfentanil With Opioid Overdose Deaths in Ohio, 2014-2017.
Topics: Adult; Analgesics, Opioid; Cocaine; Drug Overdose; Drug Trafficking; Female; Fentanyl; Heroin; Human | 2019 |
Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.
Topics: Adolescent; Adult; Analgesics, Opioid; Australia; Chronic Pain; Drug Overdose; Drug Prescriptions; F | 2019 |
Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders; Transderm | 2019 |
Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs.
Topics: Adult; Communicable Diseases; Cross-Sectional Studies; Female; Fentanyl; Humans; Ill-Housed Persons; | 2019 |
Leveraging crowdsourcing methods to collect qualitative data in addiction science: Narratives of non-medical prescription opioid, heroin, and fentanyl use.
Topics: Adult; Behavior, Addictive; Crowdsourcing; Data Collection; Feasibility Studies; Female; Fentanyl; H | 2020 |
The role of mathematical modelling in aiding public health policy decision-making: A case study of the BC opioid overdose emergency.
Topics: Analgesics, Opioid; British Columbia; Drug Overdose; Fentanyl; Health Policy; Humans; Naloxone; Opia | 2021 |
High-dose buprenorphine for treatment of high potency opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Dose-Response Relationship, Dru | 2020 |
Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid.
Topics: Administration, Intranasal; Adult; Aerosols; Analgesics, Opioid; Chromatography, High Pressure Liqui | 2020 |
Initiation of injectable opioid agonist treatment in hospital: A case report.
Topics: Analgesics, Opioid; Fentanyl; Humans; Hydromorphone; Male; Middle Aged; Opiate Substitution Treatmen | 2020 |
Potent opioids and implications for national defense.
Topics: Analgesics, Opioid; Chemical Warfare Agents; Decontamination; Drug Trafficking; Emergency Responders | 2020 |
Investigating opioid-related fatalities in southern Sweden: contact with care-providing authorities and comparison of substances.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Female; Fentanyl; Heroin; Humans; Male; Methadone; M | 2020 |
Development of an UPLC-MS/MS method for the analysis of 16 synthetic opioids in segmented hair, and evaluation of the polydrug history in fentanyl analogue users.
Topics: Analgesics, Opioid; Chromatography, High Pressure Liquid; Fentanyl; Forensic Toxicology; Hair; Human | 2020 |
An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples.
Topics: Drug Contamination; Fentanyl; Humans; Illicit Drugs; Limit of Detection; Maryland; Opioid-Related Di | 2020 |
Known fentanyl use among clients of harm reduction sites in British Columbia, Canada.
Topics: Adult; British Columbia; Female; Fentanyl; Harm Reduction; Humans; Illicit Drugs; Male; Middle Aged; | 2020 |
Evaluating the Potential for Unintentional Occupational Exposure to Fentanyl and Fentanyl Analogues Among Medicolegal Death Investigators and Autopsy Technicians.
Topics: Analgesics, Opioid; Coroners and Medical Examiners; Drug Overdose; Fentanyl; Health Personnel; Human | 2020 |
Role of Projections between Piriform Cortex and Orbitofrontal Cortex in Relapse to Fentanyl Seeking after Palatable Food Choice-Induced Voluntary Abstinence.
Topics: Analgesics, Opioid; Animals; Baclofen; Choice Behavior; Drug-Seeking Behavior; Female; Fentanyl; Foo | 2020 |
Problems with hydromorphone prescribing as a response to the opioid crisis.
Topics: Drug Prescriptions; Fentanyl; Humans; Hydromorphone; Illicit Drugs; Narcotics; Opioid Epidemic; Opio | 2020 |
Effect of positive urine fentanyl screen on attitudes toward heroin use.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Emergency Service, Hospital; Female; Fentanyl; Health Know | 2020 |
The protective effect of trusted dealers against opioid overdose in the U.S.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Harm Reduction; Humans; Male; Middle Age | 2020 |
Addressing overdose risk among unstably housed women in San Francisco, California: an examination of potential fentanyl contamination of multiple substances.
Topics: Amphetamine-Related Disorders; Comorbidity; Drug Contamination; Drug Overdose; Female; Fentanyl; Hum | 2020 |
Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Topics: Adolescent; Adult; British Columbia; Buprenorphine; Cause of Death; Cohort Studies; Emergencies; Fem | 2020 |
Is the opioid use disorder epidemic impacting our immunological health?
Topics: Analgesics, Opioid; Animals; Brain; Fentanyl; Male; Opioid-Related Disorders; Rats; Rats, Sprague-Da | 2020 |
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Fentanyl; Humans; Male; | 2021 |
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Fentanyl; Humans; Male; | 2021 |
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Fentanyl; Humans; Male; | 2021 |
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Fentanyl; Humans; Male; | 2021 |
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission.
Topics: Analgesics, Opioid; Fentanyl; Follow-Up Studies; Humans; Methadone; Opiate Substitution Treatment; O | 2020 |
Is Europe Facing an Emerging Opioid Crisis Comparable to the U.S.?
Topics: Analgesics, Opioid; Drug Overdose; Europe; Fentanyl; Humans; Opioid Epidemic; Opioid-Related Disorde | 2021 |
Protracted renal clearance of fentanyl in persons with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chromatography, Liquid; Drug Contamination; Female; Fentan | 2020 |
[Comparison of hospital consumption of immediate-release fentanyl: use or abuse?]
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Drug | 2020 |
Safer opioid distribution in response to the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Drug Overdose; Fentanyl; Global Health; Humans; Opioid-Related Disorde | 2020 |
Agency in the fentanyl era: Exploring the utility of fentanyl test strips in an opaque drug market.
Topics: Analgesics, Opioid; Baltimore; Drug Overdose; Fentanyl; Humans; Opioid-Related Disorders; Pharmaceut | 2020 |
The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York City.
Topics: Adult; Drug Contamination; Drug Overdose; Drug Users; Female; Fentanyl; Harm Reduction; Humans; Illi | 2021 |
Fentanyl vapor self-administration model in mice to study opioid addiction.
Topics: Analgesics, Opioid; Animals; Drug-Seeking Behavior; Fentanyl; Mice; Opioid-Related Disorders; Self A | 2020 |
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals.
Topics: Adult; Analgesics, Opioid; Apnea; Computer Simulation; Drug Tolerance; Female; Fentanyl; Humans; Inf | 2021 |
Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Harm Reduction; Humans | 2021 |
Delayed Norfentanyl Clearance During Pregnancy.
Topics: Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Metabolic Clearance Rate; Opioid-Related Disord | 2020 |
The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; COVID-19; Female; Fentanyl; Humans; Male; Middle Aged; | 2021 |
Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance.
Topics: Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Heroin; Humans; Illicit Drugs; Local Government | 2020 |
Sex-dependent effects of an Hnrnph1 mutation on fentanyl addiction-relevant behaviors but not antinociception in mice.
Topics: Analgesics, Opioid; Animals; Fentanyl; Heterogeneous-Nuclear Ribonucleoproteins; Male; Mice; Mice, I | 2021 |
An investigation of demographic and drug-use patterns in fentanyl and carfentanil deaths in Ontario.
Topics: Adult; Age Factors; Drug Overdose; Female; Fentanyl; Humans; Logistic Models; Male; Ontario; Opioid- | 2021 |
Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity.
Topics: Animals; Bacterial Proteins; Cattle; Diphtheria Toxin; Female; Fentanyl; Haptens; Hemocyanins; Male; | 2020 |
Addressing fentanyl-related harms: maximizing the efficiency of innovative interventions.
Topics: Analgesics, Opioid; Fentanyl; Heroin; Humans; Opioid-Related Disorders | 2021 |
A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys.
Topics: Analgesics, Opioid; Animals; Choice Behavior; Dose-Response Relationship, Drug; Feeding Behavior; Fe | 2021 |
The use of lateral flow immunoassays for the detection of fentanyl in seized drug samples and postmortem urine.
Topics: Fentanyl; Gas Chromatography-Mass Spectrometry; Humans; Illicit Drugs; Immunoassay; Opioid-Related D | 2021 |
Relative addictive potential of opioid analgesic agents.
Topics: Analgesics, Opioid; Drug Prescriptions; Fentanyl; Humans; Opioid-Related Disorders; Oxycodone; Pharm | 2021 |
Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Analgesics, Opioid; Animals; Fentanyl; Heroin; Immu | 2021 |
Selectivity and sensitivity of urine fentanyl test strips to detect fentanyl analogues in illicit drugs.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid-Related Disorders | 2021 |
Fentanyl-contaminated cocaine outbreak with laboratory confirmation in New York City in 2019.
Topics: Adult; Cocaine; Drug Overdose; Emergency Service, Hospital; Female; Fentanyl; Humans; Illicit Drugs; | 2021 |
The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic.
Topics: Attitude of Health Personnel; Comorbidity; COVID-19; Fentanyl; Humans; Opiate Overdose; Opioid Epide | 2021 |
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada.
Topics: Analgesics, Opioid; COVID-19; Fentanyl; Humans; Ontario; Opiate Substitution Treatment; Opioid Epide | 2021 |
The fentanyl phase of the opioid epidemic in Cuyahoga County, Ohio, United States.
Topics: Adult; Age Distribution; Coroners and Medical Examiners; Drug Overdose; Drug Prescriptions; Female; | 2021 |
A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse.
Topics: Animals; Buprenorphine; Conditioning, Operant; Drug-Seeking Behavior; Estrus; Female; Fentanyl; Male | 2021 |
Death associated with brorphine, an emerging novel synthetic opioid.
Topics: Analgesics, Opioid; Cause of Death; Drug Overdose; Fatal Outcome; Female; Fentanyl; Humans; Imidazol | 2021 |
A Highly Efficacious Carfentanil Vaccine That Blunts Opioid-Induced Antinociception and Respiratory Depression.
Topics: Animals; Fentanyl; Immunoconjugates; Mice; Opioid-Related Disorders; Respiratory Insufficiency; Teta | 2021 |
Reversal of ingested fentanyl patch toxicity with oral naltrexone in remote Australia: case report.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Australia; Fentanyl; Humans; Male; Naltrexone; Opio | 2021 |
Continued Increases in Overdose Deaths Related to Synthetic Opioids: Implications for Clinical Practice.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Opioid Epidemic; Opioid-Related Disorders; Synt | 2021 |
New synthetic drugs require new policies.
Topics: Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders; Policy; Synthetic Drugs | 2021 |
High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.
Topics: Analgesics, Opioid; Drug Contamination; Drug Overdose; False Positive Reactions; Fentanyl; Heroin; H | 2021 |
Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.
Topics: Analgesics, Opioid; Animals; Choice Behavior; Conditioning, Operant; Drug-Seeking Behavior; Extincti | 2021 |
Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Cocaine; COVID-19; Fentanyl; HIV Testing; Hospitaliza | 2021 |
The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
Topics: Analgesics, Opioid; Canada; Female; Fentanyl; Humans; Male; Opiate Substitution Treatment; Opioid-Re | 2021 |
Implementation of a New Hampshire community-initiated response to the opioid crisis: A mixed-methods process evaluation of Safe Station.
Topics: Emergency Service, Hospital; Fentanyl; Humans; New Hampshire; Opioid Epidemic; Opioid-Related Disord | 2021 |
Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin.
Topics: Animals; Drug Contamination; Drug Overdose; Fentanyl; Haptens; Heroin; Humans; Mice; Opioid-Related | 2021 |
Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.
Topics: Animals; Antibodies; Brain; Fentanyl; Male; Opioid-Related Disorders; Oxycodone; Rats; Vaccination; | 2021 |
Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Fentanyl; Heroin; Humans; Narcotic Antagonists; Opioid-Rel | 2021 |
Pain medication requirements in patients with opioid use disorder at the time of surgical abortion: An exploratory study.
Topics: Conscious Sedation; Female; Fentanyl; Humans; Hypnotics and Sedatives; Midazolam; Opioid-Related Dis | 2021 |
Topics: Analgesics, Opioid; Fentanyl; Humans; Methamphetamine; Opioid-Related Disorders; Substance Withdrawa | 2021 |
Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; France; Humans; Laxatives; Male; Neoplasms; Opioid-Relat | 2022 |
Predictors of intentional fentanyl use: Market availability vs consumer demand.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Opioid- | 2021 |
Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders.
Topics: Diagnosis, Dual (Psychiatry); Fentanyl; Focus Groups; Humans; Motivation; Opioid-Related Disorders; | 2018 |
Deadly chemistry.
Topics: Centers for Disease Control and Prevention, U.S.; China; Crime; Drug Overdose; Federal Government; F | 2017 |
Abuse of fentanyl derivatives: History repeating itself.
Topics: Analgesics, Opioid; Counterfeit Drugs; Fentanyl; History, 20th Century; History, 21st Century; Human | 2017 |
Variability in prescription opioid intake and reinforcement amongst 129 substrains.
Topics: Analgesics, Opioid; Animals; Fentanyl; Genetic Variation; Heroin; Male; Mice; Opioid-Related Disorde | 2017 |
Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Drug Trafficking; Female; Fentany | 2017 |
A Primer on Heroin and Fentanyl.
Topics: Drug Overdose; Fentanyl; Heroin; History, 19th Century; History, 20th Century; History, 21st Century | 2017 |
Acrylfentanyl: Another new psychoactive drug with fatal consequences.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Chromatography, Liquid; Drug Overdose; | 2017 |
Report of Increasing Overdose Deaths that include Acetyl Fentanyl in Multiple Counties of the Southwestern Region of the Commonwealth of Pennsylvania in 2015-2016.
Topics: Adult; Analgesics, Opioid; Designer Drugs; Drug Overdose; Female; Fentanyl; Gas Chromatography-Mass | 2018 |
Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
Topics: Analgesics, Opioid; Community Health Services; Drug Overdose; Fentanyl; Heroin; Heroin Dependence; H | 2017 |
US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Heroin; Heroin Dependence; Hospitalizati | 2017 |
Today's fentanyl crisis: Prohibition's Iron Law, revisited.
Topics: Analgesics, Opioid; Fentanyl; Harm Reduction; Heroin; Heroin Dependence; Humans; Illicit Drugs; Opio | 2017 |
Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'.
Topics: Adult; Drug Contamination; Drug Overdose; Drug Users; Female; Fentanyl; Harm Reduction; Heroin; Hero | 2017 |
Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Drug Contamination; Drug Overdose; Female; Fentanyl; He | 2017 |
Trends in heroin and pharmaceutical opioid overdose deaths in Australia.
Topics: Analgesics, Opioid; Australia; Drug Overdose; Fentanyl; Heroin; Humans; Morphine; Opioid-Related Dis | 2017 |
Confirmation of Carfentanil, U-47700 and Other Synthetic Opioids in a Human Performance Case by LC-MS-MS.
Topics: Analgesics, Opioid; Benzamides; Chromatography, Liquid; Fentanyl; Humans; Opioid-Related Disorders; | 2017 |
ACMT and AACT Position Statement: Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders.
Topics: Analgesics, Opioid; Emergency Responders; Eye Protective Devices; Fentanyl; Gloves, Protective; Huma | 2017 |
Controversies and carfentanil: We have much to learn about the present state of opioid poisoning.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Health Knowledge, Attitudes, Practice; Hospital Rapid R | 2017 |
Between a rock and a hard place: Prescription opioid restrictions in the time of fentanyl and other street drug adulterants.
Topics: Analgesics, Opioid; Canada; Drug Contamination; Fentanyl; Harm Reduction; Health Policy; Humans; Ill | 2017 |
Opioid Overdose Outbreak - West Virginia, August 2016.
Topics: Adolescent; Adult; Analgesics, Opioid; Designer Drugs; Disease Outbreaks; Drug Overdose; Emergency M | 2017 |
Fentanyl's Role in Opioid Overdose Deaths.
Topics: Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Humans; Male; Naloxone; Narcotic Antagonists; N | 2017 |
Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider?
Topics: Adult; Analgesics, Opioid; Disease Management; Drug Overdose; Epidemics; Evidence-Based Practice; Fe | 2018 |
Observed Carfentanil Concentrations in 355 Blood Specimens from Forensic Investigations.
Topics: Adult; Aged; Analgesics, Opioid; Chromatography, Liquid; Female; Fentanyl; Forensic Toxicology; Huma | 2017 |
Underlying Factors in Drug Overdose Deaths.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Heroin Dependence; Humans; Illicit Drugs; Mortality; Na | 2017 |
The 'fentanyl epidemic' in Canada - Some cautionary observations focusing on opioid-related mortality.
Topics: Analgesics, Opioid; Canada; Drug Overdose; Epidemics; Fentanyl; Humans; Opioid-Related Disorders; Pu | 2018 |
Fatality Following Ingestion of Tetrahydrofuranylfentanyl, U-49900 and Methoxy-Phencyclidine.
Topics: Adult; Analgesics, Opioid; Benzamides; Biotransformation; Cause of Death; Drug Overdose; Fatal Outco | 2018 |
An Unusual Amnestic Syndrome Associated With Combined Fentanyl and Cocaine Use.
Topics: Adult; Amnesia; Cocaine-Related Disorders; Fentanyl; Globus Pallidus; Hippocampus; Humans; Male; Opi | 2018 |
Rapid identification of cyclopropyl fentanyl/crotonyl fentanyl in clinical urine specimens: A case study of clinical laboratory collaboration in Canada.
Topics: Chromatography, Liquid; Female; Fentanyl; Humans; Male; Mass Spectrometry; Narcotics; Opioid-Related | 2018 |
Intravenous fentanyl use among people who inject drugs in Australia.
Topics: Adult; Australia; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Humans; Male; Middle Age | 2018 |
The distribution and redistribution of fentanyl & norfentanyl in post mortem samples.
Topics: Accidents; Analgesics, Opioid; Chromatography, Liquid; Drug Overdose; Fentanyl; Forensic Toxicology; | 2018 |
Expected and actual fentanyl exposure among persons seeking opioid withdrawal management.
Topics: Adult; Female; Fentanyl; Humans; Male; Massachusetts; Opioid-Related Disorders; Patient Acceptance o | 2018 |
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.
Topics: Adolescent; Adult; Buprenorphine; Cause of Death; Drug Overdose; Female; Fentanyl; Health Plan Imple | 2018 |
Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis.
Topics: Analgesics, Opioid; British Columbia; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Hero | 2018 |
Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations.
Topics: Analgesics, Opioid; Chronic Pain; Databases, Factual; Dose-Response Relationship, Drug; Drug Combina | 2018 |
Efficacious Vaccine against Heroin Contaminated with Fentanyl.
Topics: Analgesics, Opioid; Animals; Drug Overdose; Female; Fentanyl; Heroin; Mice, Inbred BALB C; Opioid-Re | 2018 |
The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Drug Overdose; Fentanyl; Guideline Adherence; Health | 2018 |
Facing fentanyl: should the USA consider trialling prescription heroin?
Topics: Drug Overdose; Fentanyl; Heroin; Humans; Illicit Drugs; Opioid-Related Disorders; United States | 2018 |
Time-Dependent Postmortem Redistribution of Opioids in Blood and Alternative Matrices.
Topics: Analgesics, Opioid; Autopsy; Biotransformation; Chromatography, High Pressure Liquid; Fentanyl; Fore | 2018 |
Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.
Topics: Adult; Analgesics, Opioid; British Columbia; Drug Overdose; Female; Fentanyl; Harm Reduction; Health | 2018 |
Fentanyl-associated illness among substance users - Fulton County, Georgia, 2015.
Topics: Adolescent; Adult; Aged; Amphetamine-Related Disorders; Analgesics, Opioid; Case-Control Studies; Co | 2018 |
Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Databases, Factual; Drug Prescriptions; Fentanyl; Humans | 2018 |
Carfentanil in Impaired Driving Cases and the Importance of Drug Seizure Data.
Topics: Accidents, Traffic; Analgesics, Opioid; Chromatography, Liquid; Driving Under the Influence; Drug Tr | 2018 |
Opioid Deaths in Milwaukee County, Wisconsin 2013-2017: The Primacy of Heroin and Fentanyl.
Topics: Analgesics, Opioid; Buprenorphine; Coroners and Medical Examiners; Fentanyl; Heroin; Humans; Hydroco | 2019 |
Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada.
Topics: Canada; Drug and Narcotic Control; Drug Overdose; Fentanyl; Humans; Inappropriate Prescribing; Morta | 2018 |
Addressing the growing opioid and heroin abuse epidemic: a call for medical school curricula.
Topics: Analgesics, Opioid; Awareness; Education, Medical; Fentanyl; Heroin Dependence; Humans; Opioid-Relat | 2018 |
A 52-year-old man with fentanyl-induced muscle rigidity.
Topics: Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Muscle Rigidity; Needle-Exchange Programs; | 2018 |
Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Community Health Services; Disease Outbreaks; Dr | 2019 |
Analysis of Fentanyl and 18 Novel Fentanyl Analogs and Metabolites by LC-MS-MS, and report of Fatalities Associated with Methoxyacetylfentanyl and Cyclopropylfentanyl.
Topics: Adult; Chromatography, Liquid; Drug Overdose; Female; Fentanyl; Forensic Toxicology; Humans; Limit o | 2018 |
Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?
Topics: Drug Overdose; Drug Users; Fentanyl; Humans; Opioid-Related Disorders; Reagent Strips; Self Care; Se | 2018 |
Acetyl Fentanyl: Trends and Concentrations in Metro Detroit.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Central Nervous System Depressants; Chromatography, Liqu | 2019 |
Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD.
Topics: Adolescent; Adult; Age Distribution; Aged; Analgesics, Opioid; Baltimore; Drug Contamination; Drug O | 2018 |
Parenteral Opioid Shortage - Treating Pain during the Opioid-Overdose Epidemic.
Topics: Administration, Intravenous; Analgesics, Opioid; Drug Compounding; Drug Overdose; Fentanyl; Governme | 2018 |
Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic.
Topics: Analgesics, Opioid; Drug Overdose; Epidemics; Fentanyl; Health Policy; Heroin; Humans; Illicit Drugs | 2018 |
Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Codeine; Databases, Factual; Dextropropoxyphene; Fema | 2019 |
How digital drug users could help to halt the US opioid epidemic.
Topics: Computer Simulation; Drug Overdose; Drug Tolerance; Drug Users; Drug Utilization; Emergency Service, | 2018 |
A plausible causal relationship between the increased use of fentanyl as an obstetric analgesic and the current opioid epidemic in the US.
Topics: Analgesia, Obstetrical; Analgesics, Opioid; Female; Fentanyl; Humans; Illicit Drugs; Maternal Exposu | 2018 |
Fentanyl: A Whole New World?
Topics: Analgesics, Opioid; Counterfeit Drugs; Drug Overdose; Drug Trafficking; Fentanyl; Humans; Illicit Dr | 2018 |
Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada.
Topics: Analgesics, Opioid; British Columbia; Cross-Sectional Studies; Drug Contamination; Drug Overdose; Fe | 2018 |
Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA.
Topics: Analgesics, Opioid; Antibodies; Antibody Specificity; Calibration; Cause of Death; Cross Reactions; | 2019 |
Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Hospitalization; Humans; Immunosupp | 2019 |
Commentary. Fentanyl-related death and the underreporting risk.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Forensic Toxicology; Humans; Illicit Drugs; Opioid-Rela | 2018 |
Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Heroin; Humans; Illicit Drugs; Male; Mid | 2019 |
Safety of a Modified Community Trailer to Manage Patients with Presumed Fentanyl Overdose.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Emergency Service, Hospital; Female; Fentanyl; Humans; Mal | 2019 |
Use of rapid fentanyl test strips among young adults who use drugs.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Heroin; Humans; Illicit Drugs; Male; Opi | 2018 |
Drug checking as a potential strategic overdose response in the fentanyl era.
Topics: Analgesics, Opioid; Drug Contamination; Drug Overdose; Fentanyl; Harm Reduction; Heroin; Humans; Ill | 2018 |
Civil commitment experiences among opioid users.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Drug Overdose; Female; Fentanyl; Heroin; Humans; | 2018 |
Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Act | 2018 |
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo | 2019 |
Fentanyl exposure among patients seeking opioid treatment.
Topics: Adult; Fentanyl; Heroin Dependence; Humans; Opioid-Related Disorders; Prevalence; Substance Abuse De | 2019 |
An analytically confirmed non-fatal intoxication by carfentanil in Sweden.
Topics: Adult; Analgesics, Opioid; Chromatography, Liquid; Drug Overdose; Fentanyl; Humans; Male; Opioid-Rel | 2019 |
Fatal poisoning involving cyclopropylfentanyl - Investigation of time-dependent postmortem redistribution.
Topics: Adult; Analgesics, Opioid; Chromatography, Liquid; Drug Overdose; Fentanyl; Forensic Toxicology; Gas | 2019 |
Prevalence of recent fentanyl use among treated users of illicit opioids in England: based on piloted urine drug screens.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; England; Female; Fentanyl; Humans; Male; Middle | 2019 |
Carfentanil-Associated Mortality in Wayne County, Michigan, 2015-2017.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Humans; Male; Michigan; Opioid-Related D | 2019 |
Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; British Columbia; Drug Overdose; Dyskinesia, Drug-Induced; | 2018 |
Health Care Utilization of Opioid Overdose Decedents with No Opioid Analgesic Prescription History.
Topics: Adult; Analgesics, Opioid; Black or African American; Buprenorphine; Chicago; Drug Overdose; Female; | 2019 |
"You Never Know What You're Getting": Opioid Users' Perceptions of Fentanyl in Southwest Pennsylvania.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Fentanyl; Health Knowledge, Attitudes, Practice; H | 2019 |
Healthcare Reform. Opioid Crisis.
Topics: Adolescent; Advertising; Analgesics, Opioid; Crime; Drug Industry; Drug Labeling; Drug Overdose; Edu | 2018 |
Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: Findings from the Take Home Naloxone program.
Topics: Adult; British Columbia; Cross-Sectional Studies; Drug Overdose; Emergency Medical Dispatch; Female; | 2019 |
The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Hallucinogens; Humans; Opioid Epidemic; Opioid-Related | 2019 |
Evaluation of the fentanyl patch-for-patch program in Ontario, Canada.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Emergency Service, Hospital; Fentanyl; Follow-Up Studie | 2019 |
Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017.
Topics: Adult; Aged; Aged, 80 and over; Alfentanil; Analgesics, Opioid; Female; Fentanyl; Forecasting; Human | 2019 |
Fentanyl and Drug Overdose: Perceptions of Fentanyl Risk, Overdose Risk Behaviors, and Opportunities for Intervention among People who use Opioids in Baltimore, USA.
Topics: Adult; Baltimore; Drug Overdose; Female; Fentanyl; Health Knowledge, Attitudes, Practice; Humans; Ma | 2019 |
Fentanyl: the many challenges ahead.
Topics: Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders | 2019 |
Opioid-associated amnestic syndrome observed with fentanyl patch use.
Topics: Administration, Cutaneous; Amnesia; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Midd | 2019 |
Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada.
Topics: Canada; Drug Overdose; Fentanyl; Harm Reduction; Humans; Naloxone; Narcotic Antagonists; Opioid Epid | 2019 |
Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Coc | 2019 |
Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Animals; Behavior, Animal; Choice Behavior | 2019 |
Detection of fentanyl and fentanyl analogues in biological samples using liquid chromatography-high resolution mass spectrometry.
Topics: Adult; Analgesics, Opioid; Central Nervous System Depressants; Chromatography, Liquid; Cocaine; Etha | 2019 |
The epidemiology of prescription fentanyl misuse in the United States.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Child; Female; Fentanyl; Health Surveys; Heroin Depende | 2019 |
Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl.
Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Illicit Drugs; Immunoassay; Limit of Detection; Opioi | 2019 |
"One guy goes to jail, two people are ready to take his spot": Perspectives on drug-induced homicide laws among incarcerated individuals.
Topics: Adult; Aged; Drug Overdose; Female; Fentanyl; Health Knowledge, Attitudes, Practice; Homicide; Human | 2019 |
Utility of fentanyl vaccines: unique challenges posed by preventing opioid overdose and treating opioid use disorder.
Topics: Animals; Drug Overdose; Fentanyl; Opioid-Related Disorders; Rats; Vaccines | 2019 |
Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology.
Topics: Adult; Chromatography, Liquid; Female; Fentanyl; Health Knowledge, Attitudes, Practice; Heroin Depen | 2019 |
Willingness to Use Safe Consumption Spaces among Opioid Users at High Risk of Fentanyl Overdose in Baltimore, Providence, and Boston.
Topics: Adult; Age Factors; Attitude; Cities; Confidentiality; Cross-Sectional Studies; Drug Overdose; Femal | 2019 |
The Outbreak of Fentanyl-Related Deaths in Cook County, Illinois, Between October 2015 and December 2017: A Retrospective Study and a Comparison with Previous Data.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Black or African American; Central Nervous System Depre | 2019 |
Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence.
Topics: Adult; Aged; Analgesics, Opioid; Baltimore; Black or African American; Boston; Cross-Sectional Studi | 2019 |
Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced Cocaine Overdose.
Topics: Analgesics, Opioid; Cocaine; Cocaine-Related Disorders; Computer Simulation; Drug Overdose; Fentanyl | 2019 |
The US opioid epidemic is driving a spike in infectious diseases.
Topics: Analgesics, Opioid; Communicable Diseases; Drug Users; Fentanyl; Hepatitis; Heroin; HIV Infections; | 2019 |
Fatal misuse of transdermal fentanyl patches.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Chromatography, Liquid; Female; Fentanyl; Hair; Humans; | 2019 |
Fentanyl behind bars: The implications of synthetic opiates for prisoners and correctional officers.
Topics: Adult; Analgesics, Opioid; Canada; Drug Contamination; Drug Overdose; Female; Fentanyl; Humans; Inte | 2019 |
Trends in fentanyl prescriptions and fentanyl-related mortality in Australia.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Australia; Drug Prescriptions; Female; Fentanyl; | 2013 |
Drugs, muscle pallor, and pyomyositis.
Topics: Adult; Analgesics, Opioid; Autopsy; Buttocks; Cause of Death; Drug Users; Fatal Outcome; Fentanyl; H | 2013 |
An EMS guide to chronic pain.
Topics: Analgesics, Opioid; Anticonvulsants; Biological Availability; Chronic Pain; Drug Therapy, Combinatio | 2013 |
[Dependency syndrome and hyperalgesia due to an opioid therapy for curative treatable pain. Case report of an apparent palliative patient].
Topics: Activities of Daily Living; Administration, Cutaneous; Administration, Intranasal; Aged; Analgesics, | 2013 |
Automated profile review for transdermal fentanyl to verify opioid tolerance in the military health system.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Automation; Drug Tolerance; Female; Fentanyl; | 2013 |
Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse.
Topics: Analgesics, Opioid; Breakthrough Pain; Chemoradiotherapy; Coma; Fentanyl; Gastrointestinal Stromal T | 2014 |
Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management.
Topics: Adult; Aged; Behavior, Addictive; Cohort Studies; England; Feasibility Studies; Female; Fentanyl; Hu | 2014 |
Fatal fentanyl patch misuse in a hospitalized patient with a postmortem increase in fentanyl blood concentration.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Drug Overdose; Fentanyl; Hospitalization; Humans; M | 2015 |
Compulsive-like responding for opioid analgesics in rats with extended access.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug-Seeking Behavior; Fentanyl; Heroin; Male; Opioid-Re | 2015 |
A series of forensic toxicology and drug seizure cases involving illicit fentanyl alone and in combination with heroin, cocaine or heroin and cocaine.
Topics: Adult; Aged; Autopsy; Cocaine; Female; Fentanyl; Forensic Toxicology; Heroin; Humans; Male; Middle A | 2014 |
The Fentanyl Patch Boil-Up - A Novel Method of Opioid Abuse.
Topics: Adult; Analgesics, Opioid; Chemical Fractionation; Chemistry, Pharmaceutical; Drug Overdose; Female; | 2015 |
Development and evaluation of a tampering resistant transdermal fentanyl patch.
Topics: Administration, Cutaneous; Analgesics, Opioid; Animals; Chemistry, Pharmaceutical; Drug Liberation; | 2015 |
Effectiveness of opioid analgesics in chronic noncancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Fentanyl; Humans; Hydromorphon | 2015 |
Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.
Topics: Analgesics, Opioid; Cause of Death; Drug Overdose; Europe; Fentanyl; Harm Reduction; Humans; Illicit | 2015 |
Addiction to transmucosal fentanyl: Is it a cause for concern in cancer pain management?
Topics: Administration, Mucosal; Analgesics, Opioid; Attitude of Health Personnel; Fentanyl; Humans; Neoplas | 2015 |
Schedules of Controlled Substances: Temporary Placement of Acetyl Fentanyl Into Schedule I. Final order.
Topics: Analgesics, Opioid; Designer Drugs; Drug and Narcotic Control; Fentanyl; Humans; Opioid-Related Diso | 2015 |
Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?
Topics: Analgesics, Opioid; Canada; Fentanyl; Humans; Opioid-Related Disorders; Prescription Drug Misuse | 2015 |
Intranasal Fentanyl Intoxication Leading to Diffuse Alveolar Hemorrhage.
Topics: Administration, Inhalation; Alberta; Analgesics, Opioid; Combined Modality Therapy; Diagnosis, Diffe | 2016 |
An Acute Butyr-Fentanyl Fatality: A Case Report with Postmortem Concentrations.
Topics: Adult; Analgesics, Opioid; Cocaine; Drug Overdose; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2016 |
Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
Topics: Administration, Cutaneous; Adolescent; Adult; Buprenorphine; Chronic Pain; Dose-Response Relationshi | 2016 |
Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Japan; Male; Middle Aged; O | 2017 |
Fentanyl misuse.
Topics: Analgesics, Opioid; Canada; Drug Overdose; Fentanyl; Humans; Naloxone; Narcotic Antagonists; Opioid- | 2016 |
Colonoscopy Enables the Diagnosis of Opiate Abuse.
Topics: Analgesics, Opioid; Cecum; Colonoscopy; Fentanyl; Foreign Bodies; Humans; Male; Middle Aged; Opioid- | 2016 |
Fentanyl and a Novel Synthetic Opioid U-47700 Masquerading as Street "Norco" in Central California: A Case Report.
Topics: Adult; Benzamides; California; Designer Drugs; Drug Interactions; Emergency Service, Hospital; Femal | 2017 |
Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014.
Topics: Adolescent; Adult; Aged; Drug Overdose; Female; Fentanyl; Humans; Illicit Drugs; Law Enforcement; Ma | 2016 |
Letters.
Topics: Administration, Inhalation; Adult; Analgesics, Opioid; Coma; Drug Packaging; Fentanyl; Humans; Male; | 2016 |
High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Canada; Drug Administration Schedule; Female; Fentanyl; Hospi | 2016 |
"Jaws of Steel" After Very Low Dose of Fentanyl During Prebronchoscopy Sedation.
Topics: Administration, Intravenous; Bronchoscopy; Conscious Sedation; Fentanyl; Humans; Male; Middle Aged; | 2017 |
Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically.
Topics: Adult; Analgesics, Opioid; Female; Fentanyl; Health Knowledge, Attitudes, Practice; Heroin; Humans; | 2017 |
High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance Treatment.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Fentanyl; Germany; Humans; Male; Narcotics; Opia | 2017 |
A Cluster of Fentanyl-Laced Heroin Deaths in 2015 in Melbourne, Australia.
Topics: Adult; Cause of Death; Drug Overdose; Female; Fentanyl; Forensic Toxicology; Heroin; Humans; Male; M | 2017 |
Addressing the Fentanyl Threat to Public Health.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Drug Overdose; Fentanyl; Humans; Illicit Drugs; Nalox | 2017 |
Characterizing fentanyl use in methadone-maintained clients.
Topics: Female; Fentanyl; Heroin Dependence; Humans; Male; Methadone; Michigan; Middle Aged; Opiate Substitu | 2017 |
Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications.
Topics: Adolescent; Adult; Analgesics, Opioid; Behavior, Addictive; Drug and Narcotic Control; Drug Users; F | 2009 |
Fentanyl epidemic in Chicago, Illinois and surrounding Cook County.
Topics: Adult; Cause of Death; Coroners and Medical Examiners; Databases, Factual; Drug Overdose; Emergency | 2008 |
Nonpharmaceutical fentanyl-related deaths--multiple states, April 2005-March 2007.
Topics: Adolescent; Adult; Drug Overdose; Female; Fentanyl; Humans; Male; Middle Aged; Opioid-Related Disord | 2008 |
Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationshi | 2008 |
Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Topics: Analgesics, Opioid; Animals; Benzeneacetamides; Conditioning, Operant; Dose-Response Relationship, D | 2008 |
Fentanyl and propofol exposure in the operating room: sensitization hypotheses and further data.
Topics: Air Pollutants, Occupational; Anesthesiology; Anesthetics, Intravenous; Dose-Response Relationship, | 2008 |
Trends in opioid consumption in the Nordic countries 2002-2006.
Topics: Analgesics, Opioid; Databases, Factual; Denmark; Dextropropoxyphene; Drug Administration Routes; Dru | 2009 |
Actiq: keep out of reach of children.
Topics: Analgesics, Opioid; Child; Child, Preschool; Consumer Product Safety; Drug Overdose; Fentanyl; Franc | 2008 |
The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Inverse Agonism; Fentanyl; Male; | 2009 |
The epidural works, but the patient hurts! Acute pain management of the chronic pain patient.
Topics: Acute Disease; Analgesia, Epidural; Analgesics, Opioid; Chronic Disease; Continuity of Patient Care; | 2009 |
Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause dependence.
Topics: Analgesics, Opioid; Animals; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP | 2010 |
The prevalence of fentanyl in drug-related deaths in Philadelphia 2004-2006.
Topics: Analgesics, Opioid; Autopsy; Coroners and Medical Examiners; Fentanyl; Humans; Opioid-Related Disord | 2010 |
Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Causality; Chr | 2011 |
Determinants of fentanyl and other potent µ opioid agonist misuse in opioid-dependent individuals.
Topics: Adult; Analgesics, Opioid; Data Collection; Female; Fentanyl; Humans; Male; Opioid-Related Disorders | 2010 |
Anesthesiologists and fentanyl: fact or fancy?
Topics: Anesthesiology; Cross-Sectional Studies; Fentanyl; Humans; Occupational Exposure; Opioid-Related Dis | 2010 |
Second-hand and third-hand drug exposures in the operating room: a factor in anesthesiologists' dependency on fentanyl.
Topics: Air Pollutants, Occupational; Anesthesiology; Anesthetics, Inhalation; Anesthetics, Intravenous; Bre | 2010 |
Reservations concerning second-hand fentanyl exposure in the operating room.
Topics: Air Pollutants, Occupational; Anesthetics, Inhalation; Anesthetics, Intravenous; Cross-Sectional Stu | 2010 |
Case scenario: self-extraction of intrathecal pump medication with a concomitant intrathecal granulomatous mass.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Analgesics; Analgesics, Non-Narcotic; Analgesics, O | 2011 |
Rampant caries from oral transmucosal fentanyl citrate lozenge abuse.
Topics: Administration, Buccal; Analgesics, Opioid; Cariogenic Agents; Dental Caries; Fentanyl; Humans; Male | 2011 |
Recurrent respiratory depression associated with fentanyl transdermal patch gel reservoir ingestion.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Opioid-Related Diso | 2012 |
Whole fentanyl patch ingestion: a multi-center case series.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Delayed-Action Preparations; Female; Fe | 2012 |
Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
Topics: Adamantane; Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Classical; Dipeptides; Drug | 2012 |
Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Topics: Adult; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; Fatal Outcome; Female; Fentanyl; Human | 2011 |
[Life-threatening fentanyl and propofol addiction: interview with a survivor].
Topics: Adult; Analgesics, Opioid; Anesthesiology; Anesthetics, Intravenous; Female; Fentanyl; Humans; Nalox | 2012 |
Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
Topics: Administration, Mucosal; Analgesics, Opioid; Fentanyl; Humans; Opioid-Related Disorders; Risk Assess | 2012 |
Comparison of fatal poisonings by prescription opioids.
Topics: Accidents; Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; | 2012 |
Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine.
Topics: Amphetamine-Related Disorders; Analgesics, Opioid; Animals; Central Nervous System Stimulants; Chron | 2014 |
Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006).
Topics: Adolescent; Adult; Cause of Death; Drug Contamination; Drug Overdose; Female; Fentanyl; Heroin; Huma | 2013 |
The role of fentanyl in refractory opioid-related acute colonic pseudo-obstruction.
Topics: Aged, 80 and over; Back Pain; Colonic Pseudo-Obstruction; Drug Substitution; Female; Fentanyl; Human | 2013 |
[Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
Topics: Advertising; Analgesics, Opioid; Breakthrough Pain; Drug Industry; Drug Tolerance; Education; Fentan | 2013 |
Binding affinity to and dependence on some opioids in Sf9 insect cells expressing human mu-opioid receptor.
Topics: Analgesics, Opioid; Animals; Baculoviridae; Binding, Competitive; Cells, Cultured; Cyclic AMP; Etorp | 2003 |
Drug update: Fentanyl patch abuse.
Topics: Administration, Topical; Analgesics, Opioid; Emergency Medical Services; Fentanyl; Humans; Opioid-Re | 2004 |
The opioid fentanyl affects light input, electrical activity and Per gene expression in the hamster suprachiasmatic nuclei.
Topics: Action Potentials; Animals; Behavior, Animal; Cell Cycle Proteins; Chronobiology Disorders; Circadia | 2005 |
Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients.
Topics: Analgesics, Opioid; Blood Gas Analysis; Computer Simulation; Dose-Response Relationship, Drug; Femal | 2005 |
Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients.
Topics: Analgesics, Opioid; Blood Gas Analysis; Computer Simulation; Dose-Response Relationship, Drug; Femal | 2005 |
Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients.
Topics: Analgesics, Opioid; Blood Gas Analysis; Computer Simulation; Dose-Response Relationship, Drug; Femal | 2005 |
Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients.
Topics: Analgesics, Opioid; Blood Gas Analysis; Computer Simulation; Dose-Response Relationship, Drug; Femal | 2005 |
Severe deficit in brain reward function associated with fentanyl withdrawal in rats.
Topics: Affect; Animals; Brain; Dose-Response Relationship, Drug; Fentanyl; Male; Medial Forebrain Bundle; N | 2006 |
Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Autopsy; Cause of Death; Cytochrome P-450 CYP3A; | 2005 |
Second-hand exposure to aerosolized intravenous anesthetics propofol and fentanyl may cause sensitization and subsequent opiate addiction among anesthesiologists and surgeons.
Topics: Aerosols; Air Pollutants; Air Pollution; Analgesics, Opioid; Anesthesiology; Anesthetics, Intravenou | 2006 |
Development and preliminary experience with an ease of extractability rating system for prescription opioids.
Topics: Algorithms; Analgesics, Opioid; Cluster Analysis; Drug Compounding; Drug Prescriptions; Fentanyl; Gu | 2006 |
Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Child, Preschool; Drug Admini | 2006 |
Spontaneously breathing technique for opioid tolerance.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthetics, Inhalation; Anti-Inflammatory | 2008 |
Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Drug Approval; Fentanyl; Humans; Neoplasms; Opioid-Related Diso | 2008 |
Killer fentanyl: is the fear justified?
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Global Health; Humans; Opioid-Related Disorders; Public | 2008 |
Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration.
Topics: Agmatine; Analgesics, Opioid; Animals; Area Under Curve; Data Interpretation, Statistical; Fentanyl; | 2008 |
Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving.
Topics: Adult; Analgesics, Opioid; Brain; Cocaine; Female; Fentanyl; Humans; Male; Opioid-Related Disorders; | 1996 |
Rapid opioid detoxification.
Topics: Adult; Drug Implants; Fentanyl; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; | 1998 |
Balanced analgesia for the management of pain associated with multiple fractured ribs in an opioid addict.
Topics: Adult; Amides; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Loca | 1998 |
Fentanyl self-administration in juvenile rats that were tolerant and dependent to fentanyl as infants.
Topics: Animals; Drug Tolerance; Female; Fentanyl; Naloxone; Narcotics; Opioid-Related Disorders; Quinine; R | 2000 |
Trends in medical use and abuse of opioid analgesics.
Topics: Analgesics, Opioid; Drug Utilization; Fentanyl; Humans; Hydromorphone; Meperidine; Morphine; Opioid- | 2000 |
Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl.
Topics: Analgesics, Opioid; Calibration; False Positive Reactions; Fentanyl; Humans; Immunoenzyme Techniques | 2000 |
Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Autopsy; Cause of Dea | 2000 |
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
Topics: Adrenocorticotropic Hormone; Adult; Analgesics, Opioid; Analysis of Variance; Anesthesia, General; B | 2001 |
Effects of adolescent nicotine exposure on opioid consumption and neuroendocrine responses in adult male and female rats.
Topics: Adrenocorticotropic Hormone; Aging; Analgesics, Opioid; Animals; Body Weight; Corticosterone; Drinki | 2001 |
Opioid therapy for chronic painful conditions.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Karnofsky Performan | 2001 |
Transdermal fentanyl abuse and misuse.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fatal Outcome; Fentanyl; Humans; Male; Opioid- | 2002 |
Serratia marcescens bacteremia traced to an infused narcotic.
Topics: Allied Health Personnel; Bacteremia; Disease Outbreaks; Enterobacter cloacae; Equipment Contaminatio | 2002 |
Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats.
Topics: Agmatine; Analgesics, Opioid; Animals; Body Weight; Cocaine-Related Disorders; Conditioning, Operant | 2002 |
[Opioid dependence and tolerance in the guinea-pig ileum in vitro].
Topics: Analgesics; Animals; Drug Tolerance; Fentanyl; Guinea Pigs; Ileum; Male; Morphine Derivatives; Muscl | 1990 |
Urine testing in impaired physicians.
Topics: Fentanyl; Humans; Naltrexone; Opioid-Related Disorders; Patient Compliance; Physician Impairment | 1989 |
Opioid dependence in the guinea-pig myenteric plexus is controlled by non-tolerant and tolerant opioid receptors.
Topics: Animals; Drug Tolerance; Fentanyl; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Muscle Con | 1985 |
Effect of cholera toxin and pertussis toxin on opioid tolerance and dependence in the guinea-pig myenteric plexus.
Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Animals; Cholera Toxin; Dose-Response Relationship, Drug | 1986 |
[Designer narcotics].
Topics: Amphetamines; Cocaine; Fentanyl; Humans; Meperidine; Mescaline; Narcotics; Opioid-Related Disorders | 1987 |
Opioid dependence prevents the action of pertussis toxin in the guinea-pig myenteric plexus.
Topics: Animals; Fentanyl; Guinea Pigs; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Myent | 1985 |